CZ20033377A3 - Chinuklidinové sloučeniny substituované heterocykly s několika kruhy pro léčení chorob - Google Patents
Chinuklidinové sloučeniny substituované heterocykly s několika kruhy pro léčení chorob Download PDFInfo
- Publication number
- CZ20033377A3 CZ20033377A3 CZ20033377A CZ20033377A CZ20033377A3 CZ 20033377 A3 CZ20033377 A3 CZ 20033377A3 CZ 20033377 A CZ20033377 A CZ 20033377A CZ 20033377 A CZ20033377 A CZ 20033377A CZ 20033377 A3 CZ20033377 A3 CZ 20033377A3
- Authority
- CZ
- Czechia
- Prior art keywords
- azabicyclo
- oct
- carboxamide
- pyridine
- methyl
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 75
- 201000010099 disease Diseases 0.000 title claims abstract description 50
- 238000011282 treatment Methods 0.000 title description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 370
- 239000000203 mixture Substances 0.000 claims abstract description 138
- 239000003814 drug Substances 0.000 claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 52
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 5
- -1 heteroaromatic monocyclic radicals Chemical class 0.000 claims description 236
- 125000000217 alkyl group Chemical group 0.000 claims description 136
- 239000000460 chlorine Substances 0.000 claims description 134
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 106
- 125000001424 substituent group Chemical group 0.000 claims description 87
- 229910052801 chlorine Inorganic materials 0.000 claims description 74
- 229910052731 fluorine Inorganic materials 0.000 claims description 72
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 70
- 229910052794 bromium Inorganic materials 0.000 claims description 69
- 229910052740 iodine Inorganic materials 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 64
- 229940079593 drug Drugs 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims description 53
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 46
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 41
- 208000024891 symptom Diseases 0.000 claims description 41
- 125000003342 alkenyl group Chemical group 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 39
- 125000000304 alkynyl group Chemical group 0.000 claims description 35
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 30
- 208000024827 Alzheimer disease Diseases 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 239000000164 antipsychotic agent Substances 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 150000003254 radicals Chemical class 0.000 claims description 20
- 201000000980 schizophrenia Diseases 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 18
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 18
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 17
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 16
- 230000006735 deficit Effects 0.000 claims description 16
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 16
- 208000010412 Glaucoma Diseases 0.000 claims description 15
- 208000002193 Pain Diseases 0.000 claims description 15
- 206010012289 Dementia Diseases 0.000 claims description 14
- 208000019022 Mood disease Diseases 0.000 claims description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 14
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- CZXIPBIBWCODNX-UHFFFAOYSA-N thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1=NC(C(=O)N)=CC2=C1SC=C2 CZXIPBIBWCODNX-UHFFFAOYSA-N 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 208000028017 Psychotic disease Diseases 0.000 claims description 13
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims description 13
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 230000001149 cognitive effect Effects 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 11
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 10
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 201000010374 Down Syndrome Diseases 0.000 claims description 9
- 208000023105 Huntington disease Diseases 0.000 claims description 9
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 9
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 8
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 8
- 206010039966 Senile dementia Diseases 0.000 claims description 8
- 230000003542 behavioural effect Effects 0.000 claims description 8
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 8
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 claims description 7
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 7
- 201000002832 Lewy body dementia Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 231100000870 cognitive problem Toxicity 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
- 230000005586 smoking cessation Effects 0.000 claims description 7
- MOUIXKGJJZIQSW-VFZGTOFNSA-N 3-bromo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2Br MOUIXKGJJZIQSW-VFZGTOFNSA-N 0.000 claims description 6
- RSBZVEKRAJINCU-VFZGTOFNSA-N 3-chloro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2Cl RSBZVEKRAJINCU-VFZGTOFNSA-N 0.000 claims description 6
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 6
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 6
- 206010036631 Presenile dementia Diseases 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 230000008482 dysregulation Effects 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 6
- 235000012631 food intake Nutrition 0.000 claims description 6
- JZLHKFBLZXCFNR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(Br)C2=C1 JZLHKFBLZXCFNR-ZDUSSCGKSA-N 0.000 claims description 6
- BRKZBUICSDLTJB-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2C#C BRKZBUICSDLTJB-HNNXBMFYSA-N 0.000 claims description 6
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 claims description 6
- LYSMTLRFEXVZHX-VFZGTOFNSA-N 3-bromo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2Br LYSMTLRFEXVZHX-VFZGTOFNSA-N 0.000 claims description 5
- QRZAYWIHRVMYJK-GTNSWQLSSA-N 3-ethynyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C#C QRZAYWIHRVMYJK-GTNSWQLSSA-N 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 231100000871 behavioral problem Toxicity 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- IQQNMLSLUVURHZ-UHFFFAOYSA-N furo[2,3-c]pyridine-5-carboxamide Chemical compound C1=NC(C(=O)N)=CC2=C1OC=C2 IQQNMLSLUVURHZ-UHFFFAOYSA-N 0.000 claims description 5
- 208000013403 hyperactivity Diseases 0.000 claims description 5
- HVUMNDIDTVKZBY-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(Br)C2=C1 HVUMNDIDTVKZBY-ZDUSSCGKSA-N 0.000 claims description 5
- BDVPNSZTMSWXJW-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 BDVPNSZTMSWXJW-LBPRGKRZSA-N 0.000 claims description 5
- VSFFJFOPGAUTNI-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OC=C(C)C2=C1 VSFFJFOPGAUTNI-CQSZACIVSA-N 0.000 claims description 5
- IPKZCLGGYKRDES-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2 IPKZCLGGYKRDES-CYBMUJFWSA-N 0.000 claims description 5
- YOXRCBPWSPDOQS-ZBEGNZNMSA-N 2-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC(C)=C2 YOXRCBPWSPDOQS-ZBEGNZNMSA-N 0.000 claims description 4
- IFWAAKADLPKOJB-GTNSWQLSSA-N 3-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2OC=C(CC)C2=C1 IFWAAKADLPKOJB-GTNSWQLSSA-N 0.000 claims description 4
- VHGPPUNISVTOTA-ZBEGNZNMSA-N 3-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C VHGPPUNISVTOTA-ZBEGNZNMSA-N 0.000 claims description 4
- 208000017194 Affective disease Diseases 0.000 claims description 4
- IPKZCLGGYKRDES-ZDUSSCGKSA-N Pha-543613 Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2 IPKZCLGGYKRDES-ZDUSSCGKSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 208000030963 borderline personality disease Diseases 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- XVMLNQPRWLXRIP-SGTLLEGYSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-propan-2-ylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2OC=C(C(C)C)C2=C1 XVMLNQPRWLXRIP-SGTLLEGYSA-N 0.000 claims description 4
- AMRWFRQVCKJNSX-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2 AMRWFRQVCKJNSX-BONVTDFDSA-N 0.000 claims description 4
- SZYDYQUYUGMIDV-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=CO2 SZYDYQUYUGMIDV-BONVTDFDSA-N 0.000 claims description 4
- RPKOWZMAUPGRIA-HZMBPMFUSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(C=CS2)C2=N1 RPKOWZMAUPGRIA-HZMBPMFUSA-N 0.000 claims description 4
- NAINLHWYEAPDSJ-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CC=NC=C2S1 NAINLHWYEAPDSJ-BONVTDFDSA-N 0.000 claims description 4
- HLURXESIEQDIKV-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2 HLURXESIEQDIKV-BONVTDFDSA-N 0.000 claims description 4
- OHRZCDCIGLVBCG-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=CS2 OHRZCDCIGLVBCG-BONVTDFDSA-N 0.000 claims description 4
- RVXVUHMZGCOXHD-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C(OC(C)=C2)C2=C1 RVXVUHMZGCOXHD-AWEZNQCLSA-N 0.000 claims description 4
- YCSBGDZYEYEBHT-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(Cl)C2=C1 YCSBGDZYEYEBHT-ZDUSSCGKSA-N 0.000 claims description 4
- NIKKRPJTQPOEOO-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(CC)C2=C1 NIKKRPJTQPOEOO-HNNXBMFYSA-N 0.000 claims description 4
- VHWVJYZANUDUMS-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-propan-2-ylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C(C)C)C2=C1 VHWVJYZANUDUMS-INIZCTEOSA-N 0.000 claims description 4
- ZSGKCMMGDSDZDP-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[3,2-c]pyridine-3-carboxamide Chemical compound O1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@@H]1C(CC2)CCN2C1 ZSGKCMMGDSDZDP-INIZCTEOSA-N 0.000 claims description 4
- KYCAUWHYDUAAJT-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[2,3-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(N[C@@H]1C3CCN(CC3)C1)=O)=C2 KYCAUWHYDUAAJT-INIZCTEOSA-N 0.000 claims description 4
- YMZFSPQBWIIQLA-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CO2 YMZFSPQBWIIQLA-ZDUSSCGKSA-N 0.000 claims description 4
- SHNXADNAVHWLIZ-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-6-carboxamide Chemical compound C1=C2C=CSC2=NC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 SHNXADNAVHWLIZ-ZDUSSCGKSA-N 0.000 claims description 4
- ZSGZDXFSNNPGIH-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 ZSGZDXFSNNPGIH-LBPRGKRZSA-N 0.000 claims description 4
- NJNIZJCRCANYGV-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2 NJNIZJCRCANYGV-ZDUSSCGKSA-N 0.000 claims description 4
- CKZPWHBWHVGFPO-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CS2 CKZPWHBWHVGFPO-ZDUSSCGKSA-N 0.000 claims description 4
- RVXVUHMZGCOXHD-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C(OC(C)=C2)C2=C1 RVXVUHMZGCOXHD-CQSZACIVSA-N 0.000 claims description 4
- HVUMNDIDTVKZBY-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OC=C(Br)C2=C1 HVUMNDIDTVKZBY-CYBMUJFWSA-N 0.000 claims description 4
- JZLHKFBLZXCFNR-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2SC=C(Br)C2=C1 JZLHKFBLZXCFNR-CYBMUJFWSA-N 0.000 claims description 4
- YCSBGDZYEYEBHT-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OC=C(Cl)C2=C1 YCSBGDZYEYEBHT-CYBMUJFWSA-N 0.000 claims description 4
- BRKZBUICSDLTJB-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2C#C BRKZBUICSDLTJB-OAHLLOKOSA-N 0.000 claims description 4
- BDVPNSZTMSWXJW-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2OC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 BDVPNSZTMSWXJW-GFCCVEGCSA-N 0.000 claims description 4
- ZSGZDXFSNNPGIH-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 ZSGZDXFSNNPGIH-GFCCVEGCSA-N 0.000 claims description 4
- CKZPWHBWHVGFPO-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CS2 CKZPWHBWHVGFPO-CYBMUJFWSA-N 0.000 claims description 4
- TUPZWIXDHKKDRH-UHFFFAOYSA-N thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1=NC(C(=O)N)=CC2=C1C=CS2 TUPZWIXDHKKDRH-UHFFFAOYSA-N 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 3
- ZNDMIWBPVKVUMQ-BUXKBTBVSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[2,3-c]pyridine-3-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC(C2=CC=CC=C2S2)=C2C=N1 ZNDMIWBPVKVUMQ-BUXKBTBVSA-N 0.000 claims description 3
- POEAWSFIYJPHLM-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,4-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CSC=C2C=N1 POEAWSFIYJPHLM-BONVTDFDSA-N 0.000 claims description 3
- VSFFJFOPGAUTNI-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C)C2=C1 VSFFJFOPGAUTNI-AWEZNQCLSA-N 0.000 claims description 3
- OJHDSYCOAYLDKX-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-2-carboxamide Chemical compound C1=CC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=N1 OJHDSYCOAYLDKX-LBPRGKRZSA-N 0.000 claims description 3
- FSWJILNACZEMQN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,4-c]pyridine-6-carboxamide Chemical compound C=1C2=CSC=C2C=NC=1C(=O)N[C@@H]1C(CC2)CCN2C1 FSWJILNACZEMQN-AWEZNQCLSA-N 0.000 claims description 3
- VHWVJYZANUDUMS-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-propan-2-ylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OC=C(C(C)C)C2=C1 VHWVJYZANUDUMS-MRXNPFEDSA-N 0.000 claims description 3
- ZSGKCMMGDSDZDP-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[3,2-c]pyridine-3-carboxamide Chemical compound O1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@H]1C(CC2)CCN2C1 ZSGKCMMGDSDZDP-MRXNPFEDSA-N 0.000 claims description 3
- KYCAUWHYDUAAJT-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[2,3-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(N[C@H]1C3CCN(CC3)C1)=O)=C2 KYCAUWHYDUAAJT-MRXNPFEDSA-N 0.000 claims description 3
- DGAPFHWBXIIYFB-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2OC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 DGAPFHWBXIIYFB-GFCCVEGCSA-N 0.000 claims description 3
- YMZFSPQBWIIQLA-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CO2 YMZFSPQBWIIQLA-CYBMUJFWSA-N 0.000 claims description 3
- MRERTYLGKXMNLX-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 MRERTYLGKXMNLX-GFCCVEGCSA-N 0.000 claims description 3
- SHNXADNAVHWLIZ-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-6-carboxamide Chemical compound C1=C2C=CSC2=NC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 SHNXADNAVHWLIZ-CYBMUJFWSA-N 0.000 claims description 3
- NJNIZJCRCANYGV-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2 NJNIZJCRCANYGV-CYBMUJFWSA-N 0.000 claims description 3
- FSWJILNACZEMQN-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,4-c]pyridine-6-carboxamide Chemical compound C=1C2=CSC=C2C=NC=1C(=O)N[C@H]1C(CC2)CCN2C1 FSWJILNACZEMQN-CQSZACIVSA-N 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- HFTJXSHQIDPAIM-ZBEGNZNMSA-N 1-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]pyrrolo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1N(C)C=C2 HFTJXSHQIDPAIM-ZBEGNZNMSA-N 0.000 claims description 2
- RATMFLZWYDFERT-VFZGTOFNSA-N 2-bromo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(Br)O2 RATMFLZWYDFERT-VFZGTOFNSA-N 0.000 claims description 2
- WFMAMKZWRULFIS-VFZGTOFNSA-N 2-bromo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(Br)S2 WFMAMKZWRULFIS-VFZGTOFNSA-N 0.000 claims description 2
- VZGLFCZPBUXNLF-VFZGTOFNSA-N 2-chloro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(Cl)O2 VZGLFCZPBUXNLF-VFZGTOFNSA-N 0.000 claims description 2
- KKDLSBYVIGWZPQ-VFZGTOFNSA-N 2-chloro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(Cl)S2 KKDLSBYVIGWZPQ-VFZGTOFNSA-N 0.000 claims description 2
- HZWVDHNBMUDOJI-QFYYESIMSA-N 2-cyano-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C#N)O2 HZWVDHNBMUDOJI-QFYYESIMSA-N 0.000 claims description 2
- GHOQDSVTOLDBAH-QFYYESIMSA-N 2-cyano-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C#N)S2 GHOQDSVTOLDBAH-QFYYESIMSA-N 0.000 claims description 2
- ONKWYDSYCFNOCB-GTNSWQLSSA-N 2-ethenyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C=C)O2 ONKWYDSYCFNOCB-GTNSWQLSSA-N 0.000 claims description 2
- SMWKYNIVPRSPEI-GTNSWQLSSA-N 2-ethenyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C=C)S2 SMWKYNIVPRSPEI-GTNSWQLSSA-N 0.000 claims description 2
- LYVBYUMDTQGRAO-GTNSWQLSSA-N 2-ethynyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C#C)O2 LYVBYUMDTQGRAO-GTNSWQLSSA-N 0.000 claims description 2
- CUYKQIWIGONQTQ-GTNSWQLSSA-N 2-ethynyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C#C)S2 CUYKQIWIGONQTQ-GTNSWQLSSA-N 0.000 claims description 2
- SBLYMEZKDSJLKQ-VFZGTOFNSA-N 2-fluoro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(F)S2 SBLYMEZKDSJLKQ-VFZGTOFNSA-N 0.000 claims description 2
- BFBWQGVBHUHFCC-QFYYESIMSA-N 2-formyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C=O)O2 BFBWQGVBHUHFCC-QFYYESIMSA-N 0.000 claims description 2
- SHIQKQJQJYXFDM-QFYYESIMSA-N 2-formyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C=O)S2 SHIQKQJQJYXFDM-QFYYESIMSA-N 0.000 claims description 2
- FSTUCRSJNMSJBE-VFZGTOFNSA-N 2-iodo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(I)O2 FSTUCRSJNMSJBE-VFZGTOFNSA-N 0.000 claims description 2
- SVFNYEVBLVRRBG-VFZGTOFNSA-N 2-iodo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(I)S2 SVFNYEVBLVRRBG-VFZGTOFNSA-N 0.000 claims description 2
- GWISADSJRZFCFA-ZBEGNZNMSA-N 3,3-dimethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2h-furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OCC2(C)C GWISADSJRZFCFA-ZBEGNZNMSA-N 0.000 claims description 2
- RARMJEGURAREPE-VOJFVSQTSA-N 3-[5-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[2,3-c]pyridin-3-yl]prop-2-ynoic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C#CC(O)=O RARMJEGURAREPE-VOJFVSQTSA-N 0.000 claims description 2
- IKQJKFGXFJMEBK-VOJFVSQTSA-N 3-[5-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[2,3-c]pyridin-3-yl]prop-2-ynoic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C#CC(O)=O IKQJKFGXFJMEBK-VOJFVSQTSA-N 0.000 claims description 2
- AUIJBOPGKBKSKN-VOJFVSQTSA-N 3-[6-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[3,2-c]pyridin-2-yl]prop-2-ynoic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C#CC(O)=O)S2 AUIJBOPGKBKSKN-VOJFVSQTSA-N 0.000 claims description 2
- WLQCDGAETPDAGB-VFZGTOFNSA-N 3-chloro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2Cl WLQCDGAETPDAGB-VFZGTOFNSA-N 0.000 claims description 2
- FUPQNJIPZAGDCX-QFYYESIMSA-N 3-cyano-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C#N FUPQNJIPZAGDCX-QFYYESIMSA-N 0.000 claims description 2
- GMONOBUIBYANSG-QFYYESIMSA-N 3-cyano-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C#N GMONOBUIBYANSG-QFYYESIMSA-N 0.000 claims description 2
- LEOKAUPAOUFHTI-GTNSWQLSSA-N 3-ethenyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C=C LEOKAUPAOUFHTI-GTNSWQLSSA-N 0.000 claims description 2
- ZAYDLIOJGLVYGO-GTNSWQLSSA-N 3-ethenyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C=C ZAYDLIOJGLVYGO-GTNSWQLSSA-N 0.000 claims description 2
- INWMUDAVJZDCIY-GTNSWQLSSA-N 3-ethynyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C#C INWMUDAVJZDCIY-GTNSWQLSSA-N 0.000 claims description 2
- BHRKTLYJYRKMHF-VFZGTOFNSA-N 3-fluoro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2F BHRKTLYJYRKMHF-VFZGTOFNSA-N 0.000 claims description 2
- RHLDGTRPBVEPKE-QFYYESIMSA-N 3-formyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C=O RHLDGTRPBVEPKE-QFYYESIMSA-N 0.000 claims description 2
- JQSSUIQRZOPQLZ-QFYYESIMSA-N 3-formyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C=O JQSSUIQRZOPQLZ-QFYYESIMSA-N 0.000 claims description 2
- GTNFVZBVQLFKQY-VFZGTOFNSA-N 5-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[2,3-c]pyridine-3-carboxylic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C(O)=O GTNFVZBVQLFKQY-VFZGTOFNSA-N 0.000 claims description 2
- HATNIVPQHPPODQ-VFZGTOFNSA-N 5-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[2,3-c]pyridine-3-carboxylic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C(O)=O HATNIVPQHPPODQ-VFZGTOFNSA-N 0.000 claims description 2
- GDCGSOGYDOFTMI-ZDUSSCGKSA-N 5-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[2,3-c]pyridine-3-carboxylic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C(=O)O)C2=C1 GDCGSOGYDOFTMI-ZDUSSCGKSA-N 0.000 claims description 2
- CCWGCCFAVGYNDJ-ZDUSSCGKSA-N 5-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[2,3-c]pyridine-3-carboxylic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C(=O)O)C2=C1 CCWGCCFAVGYNDJ-ZDUSSCGKSA-N 0.000 claims description 2
- YMLWSKLMDHVQKB-VFZGTOFNSA-N 6-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[3,2-c]pyridine-2-carboxylic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C(O)=O)O2 YMLWSKLMDHVQKB-VFZGTOFNSA-N 0.000 claims description 2
- HZMYJKJXRQCLOD-LBPRGKRZSA-N 6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[3,2-c]pyridine-2-carboxylic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C(=O)O)OC2=C1 HZMYJKJXRQCLOD-LBPRGKRZSA-N 0.000 claims description 2
- NAAAIDNFNBTNFQ-ZANVPECISA-N 7-chloro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1Cl)=CC2=C1OC=C2 NAAAIDNFNBTNFQ-ZANVPECISA-N 0.000 claims description 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- OKJUGSGVLGUIFP-AWEZNQCLSA-N C1CN2CCC1[C@H](C2)N3C=CC4=C(COC4=C3)N5C=CN=N5 Chemical compound C1CN2CCC1[C@H](C2)N3C=CC4=C(COC4=C3)N5C=CN=N5 OKJUGSGVLGUIFP-AWEZNQCLSA-N 0.000 claims description 2
- UFGIDQVWKGWGRO-AWEZNQCLSA-N C1CN2CCC1[C@H](C2)N3C=CC4=C(COC4=C3)N5C=NC=N5 Chemical compound C1CN2CCC1[C@H](C2)N3C=CC4=C(COC4=C3)N5C=NC=N5 UFGIDQVWKGWGRO-AWEZNQCLSA-N 0.000 claims description 2
- FEVQFXFENDJDOV-UGSOOPFHSA-N C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5C=CN=C5 Chemical compound C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5C=CN=C5 FEVQFXFENDJDOV-UGSOOPFHSA-N 0.000 claims description 2
- ARYGECUJTHLRPC-DJJJIMSYSA-N C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5CCNC(=O)C5 Chemical compound C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5CCNC(=O)C5 ARYGECUJTHLRPC-DJJJIMSYSA-N 0.000 claims description 2
- UTWZSOWJXQBTCF-DJJJIMSYSA-N C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5CCOCC5=O Chemical compound C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5CCOCC5=O UTWZSOWJXQBTCF-DJJJIMSYSA-N 0.000 claims description 2
- 208000028964 Congenital reticular ichthyosiform erythroderma Diseases 0.000 claims description 2
- NGOIFLIWDZQUSK-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrrolo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1NC=C2 NGOIFLIWDZQUSK-BONVTDFDSA-N 0.000 claims description 2
- GBAWMOOGNRCEIJ-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2,3-dihydrofuro[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OCC2 GBAWMOOGNRCEIJ-BONVTDFDSA-N 0.000 claims description 2
- QFBAIWVETQQJMF-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-(trifluoromethyl)furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C(F)(F)F)O2 QFBAIWVETQQJMF-VFZGTOFNSA-N 0.000 claims description 2
- OWTPXTGPUFNEFO-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-(trifluoromethyl)thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C(F)(F)F)S2 OWTPXTGPUFNEFO-VFZGTOFNSA-N 0.000 claims description 2
- JSUJGKNTKVTIMB-SGTLLEGYSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-prop-1-ynylfuro[3,2-c]pyridine-6-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2C=C(C#CC)OC2=C1 JSUJGKNTKVTIMB-SGTLLEGYSA-N 0.000 claims description 2
- ULLRKXJWAHFVAX-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-sulfanylfuro[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(S)O2 ULLRKXJWAHFVAX-VFZGTOFNSA-N 0.000 claims description 2
- GUPYMTMXCSKCQI-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-sulfanylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(S)S2 GUPYMTMXCSKCQI-VFZGTOFNSA-N 0.000 claims description 2
- BYXXHRLIIGIKHS-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-(trifluoromethyl)furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C(F)(F)F BYXXHRLIIGIKHS-VFZGTOFNSA-N 0.000 claims description 2
- XJMMNBDRQHWPEN-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-(trifluoromethyl)thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C(F)(F)F XJMMNBDRQHWPEN-VFZGTOFNSA-N 0.000 claims description 2
- AJXOXEFLWMRIOP-SGTLLEGYSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2OC=C(C#CC)C2=C1 AJXOXEFLWMRIOP-SGTLLEGYSA-N 0.000 claims description 2
- DAPOUYROVRHYDT-SGTLLEGYSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-prop-1-ynylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2SC=C(C#CC)C2=C1 DAPOUYROVRHYDT-SGTLLEGYSA-N 0.000 claims description 2
- DIILQJFDXZTHNA-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-sulfanylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2S DIILQJFDXZTHNA-VFZGTOFNSA-N 0.000 claims description 2
- FDRCUBQXQOHXTG-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-sulfanylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2S FDRCUBQXQOHXTG-VFZGTOFNSA-N 0.000 claims description 2
- RISTWJRRDGELMS-BUXKBTBVSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[2,3-c]pyridine-3-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC(C2=CC=CC=C2O2)=C2C=N1 RISTWJRRDGELMS-BUXKBTBVSA-N 0.000 claims description 2
- ZIDUDESSRYFLPU-BUXKBTBVSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[3,2-c]pyridine-3-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C1=CC=CC=C1S2 ZIDUDESSRYFLPU-BUXKBTBVSA-N 0.000 claims description 2
- WHQLQXNZOITJIM-HZMBPMFUSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-b]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CC=CN=C2O1 WHQLQXNZOITJIM-HZMBPMFUSA-N 0.000 claims description 2
- MWXFWIANVDHCBP-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CC=NC=C2O1 MWXFWIANVDHCBP-BONVTDFDSA-N 0.000 claims description 2
- APXXZFYJXUHKNX-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,4-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=COC=C2C=N1 APXXZFYJXUHKNX-BONVTDFDSA-N 0.000 claims description 2
- XQEFNJASUQFISC-HZMBPMFUSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CN=C(SC=C2)C2=C1 XQEFNJASUQFISC-HZMBPMFUSA-N 0.000 claims description 2
- YEVQVRSQGKNNFB-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=NC=CC=C2S1 YEVQVRSQGKNNFB-BONVTDFDSA-N 0.000 claims description 2
- DCGZPTATTXTVRS-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(SC=C2)C2=N1 DCGZPTATTXTVRS-BONVTDFDSA-N 0.000 claims description 2
- XGEIUDHYUFOLGP-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CN=C(C=CS2)C2=C1 XGEIUDHYUFOLGP-BONVTDFDSA-N 0.000 claims description 2
- XVKYYUUVAFBGBX-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CN=CC=C2S1 XVKYYUUVAFBGBX-BONVTDFDSA-N 0.000 claims description 2
- DFPSNUNFNPWITQ-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1-methylpyrrolo[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2N(C)C=CC2=C1 DFPSNUNFNPWITQ-AWEZNQCLSA-N 0.000 claims description 2
- QFCSKKDBNVRDQV-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-dihydrofuro[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OCC2 QFCSKKDBNVRDQV-ZDUSSCGKSA-N 0.000 claims description 2
- OXXZSAFHKNDCIN-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-(trifluoromethyl)thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C(F)(F)F)SC2=C1 OXXZSAFHKNDCIN-LBPRGKRZSA-N 0.000 claims description 2
- MCNCUNXFFXEARZ-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-chlorofuro[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(Cl)OC2=C1 MCNCUNXFFXEARZ-LBPRGKRZSA-N 0.000 claims description 2
- OCZPHYJTEFONKI-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-chlorothieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(Cl)SC2=C1 OCZPHYJTEFONKI-LBPRGKRZSA-N 0.000 claims description 2
- LWVHCSQCKPNPJG-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyanofuro[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=C(C#N)O2 LWVHCSQCKPNPJG-AWEZNQCLSA-N 0.000 claims description 2
- IESDNJYVPZVDJR-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethenylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C=C)SC2=C1 IESDNJYVPZVDJR-HNNXBMFYSA-N 0.000 claims description 2
- WHAMKZWZQNMYHL-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethynylfuro[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=C(C#C)O2 WHAMKZWZQNMYHL-HNNXBMFYSA-N 0.000 claims description 2
- TXSHFKFYDBKQKL-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethynylthieno[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=C(C#C)S2 TXSHFKFYDBKQKL-HNNXBMFYSA-N 0.000 claims description 2
- QQFLZTVCTNGWCQ-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-fluorothieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(F)SC2=C1 QQFLZTVCTNGWCQ-LBPRGKRZSA-N 0.000 claims description 2
- OUEVXULKRYRQPA-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-formylfuro[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C=O)OC2=C1 OUEVXULKRYRQPA-AWEZNQCLSA-N 0.000 claims description 2
- PGELRXDVDGPJCC-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-iodofuro[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(I)OC2=C1 PGELRXDVDGPJCC-LBPRGKRZSA-N 0.000 claims description 2
- QUAZABKXISSQMI-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-iodothieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(I)SC2=C1 QUAZABKXISSQMI-LBPRGKRZSA-N 0.000 claims description 2
- ZWRODXXDXWEMKV-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-prop-1-ynylfuro[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C#CC)OC2=C1 ZWRODXXDXWEMKV-INIZCTEOSA-N 0.000 claims description 2
- CMDDJPYGEIMNOX-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-prop-1-ynylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C#CC)SC2=C1 CMDDJPYGEIMNOX-INIZCTEOSA-N 0.000 claims description 2
- WEWVHODRKIDELE-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-sulfanylfuro[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(S)OC2=C1 WEWVHODRKIDELE-LBPRGKRZSA-N 0.000 claims description 2
- KBRLIPRWHKIQFC-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-sulfanylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(S)SC2=C1 KBRLIPRWHKIQFC-LBPRGKRZSA-N 0.000 claims description 2
- RPAQKNMPMUTPBE-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3,3-dimethyl-2h-furo[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OCC(C)(C)C2=C1 RPAQKNMPMUTPBE-AWEZNQCLSA-N 0.000 claims description 2
- KAIMJRMQKIFTLJ-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(trifluoromethyl)furo[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C(F)(F)F)C2=C1 KAIMJRMQKIFTLJ-ZDUSSCGKSA-N 0.000 claims description 2
- UUQSMBNSSYAEBK-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(trifluoromethyl)thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C(F)(F)F)C2=C1 UUQSMBNSSYAEBK-ZDUSSCGKSA-N 0.000 claims description 2
- USCXOKXKBVJNGO-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-chlorothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(Cl)C2=C1 USCXOKXKBVJNGO-ZDUSSCGKSA-N 0.000 claims description 2
- SXPBPHDGAXTQLO-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2C#N SXPBPHDGAXTQLO-AWEZNQCLSA-N 0.000 claims description 2
- LUEXKOGGZCIXMK-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-cyanothieno[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2C#N LUEXKOGGZCIXMK-AWEZNQCLSA-N 0.000 claims description 2
- VOKHGYRIBDYBEF-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethenylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C=C)C2=C1 VOKHGYRIBDYBEF-HNNXBMFYSA-N 0.000 claims description 2
- SZHVWEBGUSKQAP-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-fluorothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(F)C2=C1 SZHVWEBGUSKQAP-ZDUSSCGKSA-N 0.000 claims description 2
- NFPOLIAIJYGFCN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-formylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C=O)C2=C1 NFPOLIAIJYGFCN-AWEZNQCLSA-N 0.000 claims description 2
- SQQWAXFLSKVQHZ-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-formylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C=O)C2=C1 SQQWAXFLSKVQHZ-AWEZNQCLSA-N 0.000 claims description 2
- KRXBETLATVVYCL-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-iodothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(I)C2=C1 KRXBETLATVVYCL-ZDUSSCGKSA-N 0.000 claims description 2
- XGRQNDGMEYPKIB-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C#CC)C2=C1 XGRQNDGMEYPKIB-INIZCTEOSA-N 0.000 claims description 2
- UEVVMXZSVXHGBL-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-prop-1-ynylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C#CC)C2=C1 UEVVMXZSVXHGBL-INIZCTEOSA-N 0.000 claims description 2
- LZRXHFQEEMXOCK-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-sulfanylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(S)C2=C1 LZRXHFQEEMXOCK-LBPRGKRZSA-N 0.000 claims description 2
- DVQFBOTYMHGMHZ-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chlorofuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C(N=C1Cl)=CC2=C1OC=C2 DVQFBOTYMHGMHZ-LBPRGKRZSA-N 0.000 claims description 2
- DCTUPJPSCABRHP-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-methoxyfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C(N=C1OC)=CC2=C1OC=C2 DCTUPJPSCABRHP-ZDUSSCGKSA-N 0.000 claims description 2
- PXSUUTRGRAOOHS-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C(N=C1C)=CC2=C1OC=C2 PXSUUTRGRAOOHS-AWEZNQCLSA-N 0.000 claims description 2
- MZQSJUPWLIOLPC-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[2,3-c]pyridine-3-carboxamide Chemical compound O1C2=CC=CC=C2C2=C1C=NC(C(N[C@@H]1C3CCN(CC3)C1)=O)=C2 MZQSJUPWLIOLPC-INIZCTEOSA-N 0.000 claims description 2
- JMDKTKWBOZYREH-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[3,2-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@@H]1C(CC2)CCN2C1 JMDKTKWBOZYREH-INIZCTEOSA-N 0.000 claims description 2
- DGAPFHWBXIIYFB-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 DGAPFHWBXIIYFB-LBPRGKRZSA-N 0.000 claims description 2
- QRRVGHRZQSUBCR-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 QRRVGHRZQSUBCR-LBPRGKRZSA-N 0.000 claims description 2
- SVIPJXPWUBBXDN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,4-c]pyridine-6-carboxamide Chemical compound C=1C2=COC=C2C=NC=1C(=O)N[C@@H]1C(CC2)CCN2C1 SVIPJXPWUBBXDN-AWEZNQCLSA-N 0.000 claims description 2
- MRERTYLGKXMNLX-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 MRERTYLGKXMNLX-LBPRGKRZSA-N 0.000 claims description 2
- ZLAYHELXVXRZHE-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-5-carboxamide Chemical compound N1=C2SC=CC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 ZLAYHELXVXRZHE-ZDUSSCGKSA-N 0.000 claims description 2
- GLSTVJODWGVAMW-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-5-carboxamide Chemical compound C1=C2SC=CC2=NC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 GLSTVJODWGVAMW-ZDUSSCGKSA-N 0.000 claims description 2
- CKBIGORMZMVQRP-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-6-carboxamide Chemical compound N1=C2C=CSC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 CKBIGORMZMVQRP-ZDUSSCGKSA-N 0.000 claims description 2
- GTPGKSNYGZTLQJ-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 GTPGKSNYGZTLQJ-LBPRGKRZSA-N 0.000 claims description 2
- DFPSNUNFNPWITQ-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-methylpyrrolo[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2N(C)C=CC2=C1 DFPSNUNFNPWITQ-CQSZACIVSA-N 0.000 claims description 2
- PDGSKMBKOMNHDR-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrrolo[2,3-c]pyridine-5-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1NC=C2 PDGSKMBKOMNHDR-CQSZACIVSA-N 0.000 claims description 2
- QFCSKKDBNVRDQV-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-dihydrofuro[2,3-c]pyridine-5-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OCC2 QFCSKKDBNVRDQV-CYBMUJFWSA-N 0.000 claims description 2
- NIKKRPJTQPOEOO-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OC=C(CC)C2=C1 NIKKRPJTQPOEOO-OAHLLOKOSA-N 0.000 claims description 2
- DVQFBOTYMHGMHZ-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-chlorofuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C(N=C1Cl)=CC2=C1OC=C2 DVQFBOTYMHGMHZ-GFCCVEGCSA-N 0.000 claims description 2
- JMDKTKWBOZYREH-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[3,2-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@H]1C(CC2)CCN2C1 JMDKTKWBOZYREH-MRXNPFEDSA-N 0.000 claims description 2
- QRRVGHRZQSUBCR-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2OC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 QRRVGHRZQSUBCR-GFCCVEGCSA-N 0.000 claims description 2
- ZLAYHELXVXRZHE-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-5-carboxamide Chemical compound N1=C2SC=CC2=CC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 ZLAYHELXVXRZHE-CYBMUJFWSA-N 0.000 claims description 2
- OJHDSYCOAYLDKX-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-2-carboxamide Chemical compound C1=CC=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=N1 OJHDSYCOAYLDKX-GFCCVEGCSA-N 0.000 claims description 2
- GLSTVJODWGVAMW-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-5-carboxamide Chemical compound C1=C2SC=CC2=NC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 GLSTVJODWGVAMW-CYBMUJFWSA-N 0.000 claims description 2
- CKBIGORMZMVQRP-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-6-carboxamide Chemical compound N1=C2C=CSC2=CC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 CKBIGORMZMVQRP-CYBMUJFWSA-N 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims 4
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 claims 3
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 3
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 3
- SICPAMXMBBLYMG-HNNXBMFYSA-N 3-[5-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[2,3-c]pyridin-3-yl]prop-2-ynoic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C#CC(=O)O)C2=C1 SICPAMXMBBLYMG-HNNXBMFYSA-N 0.000 claims 1
- IZMFDWXILINUPQ-HNNXBMFYSA-N 3-[5-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[2,3-c]pyridin-3-yl]prop-2-ynoic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C#CC(=O)O)C2=C1 IZMFDWXILINUPQ-HNNXBMFYSA-N 0.000 claims 1
- AZDHJIUEIDOVNE-VOJFVSQTSA-N 3-[6-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[3,2-c]pyridin-2-yl]prop-2-ynoic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C#CC(O)=O)O2 AZDHJIUEIDOVNE-VOJFVSQTSA-N 0.000 claims 1
- AQUFNWRDAUPHFO-HNNXBMFYSA-N 3-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[3,2-c]pyridin-2-yl]prop-2-ynoic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C#CC(=O)O)OC2=C1 AQUFNWRDAUPHFO-HNNXBMFYSA-N 0.000 claims 1
- JAMWWNGSVCRYHU-HNNXBMFYSA-N 3-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[3,2-c]pyridin-2-yl]prop-2-ynoic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C#CC(=O)O)SC2=C1 JAMWWNGSVCRYHU-HNNXBMFYSA-N 0.000 claims 1
- ACVVDBHYRWNBHD-VFZGTOFNSA-N 3-iodo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2I ACVVDBHYRWNBHD-VFZGTOFNSA-N 0.000 claims 1
- UEASRLFBOHSXFW-VFZGTOFNSA-N 6-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[3,2-c]pyridine-2-carboxylic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C(O)=O)S2 UEASRLFBOHSXFW-VFZGTOFNSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 210000002816 gill Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KXMPVGDWAMTMMH-SGTLLEGYSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-prop-1-ynylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2C=C(C#CC)SC2=C1 KXMPVGDWAMTMMH-SGTLLEGYSA-N 0.000 claims 1
- VTXLFWSHOAIAQR-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyanothieno[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=C(C#N)S2 VTXLFWSHOAIAQR-AWEZNQCLSA-N 0.000 claims 1
- UYEVTNKCLBSBCI-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-formylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C=O)SC2=C1 UYEVTNKCLBSBCI-AWEZNQCLSA-N 0.000 claims 1
- ZXRADJSLTKHSCR-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethenylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C=C)C2=C1 ZXRADJSLTKHSCR-HNNXBMFYSA-N 0.000 claims 1
- GZSFTYCFESHMTJ-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-iodofuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(I)C2=C1 GZSFTYCFESHMTJ-ZDUSSCGKSA-N 0.000 claims 1
- ANNOWMBWHHKGLN-UHFFFAOYSA-N pyridine-3,5-dicarboxamide Chemical compound NC(=O)C1=CN=CC(C(N)=O)=C1 ANNOWMBWHHKGLN-UHFFFAOYSA-N 0.000 claims 1
- RXGHULSMJIVVTA-UHFFFAOYSA-N thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2SC(C(=O)N)=CC2=C1 RXGHULSMJIVVTA-UHFFFAOYSA-N 0.000 claims 1
- MKYRMMMSZSVIGD-UHFFFAOYSA-N thieno[3,2-c]pyridine Chemical compound N1=CC=C2SC=CC2=C1 MKYRMMMSZSVIGD-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 245
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 231
- 239000007787 solid Substances 0.000 description 173
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 161
- 239000000243 solution Substances 0.000 description 154
- 239000011541 reaction mixture Substances 0.000 description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 105
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 102
- 235000019439 ethyl acetate Nutrition 0.000 description 93
- 230000002829 reductive effect Effects 0.000 description 89
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 87
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 85
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 65
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 64
- 239000012044 organic layer Substances 0.000 description 64
- UPUKXPTXCGNQJR-UHFFFAOYSA-N 2-chloro-6-(hydroxymethyl)-4-(2-trimethylsilylethynyl)pyridin-3-ol Chemical compound C[Si](C)(C)C#CC1=CC(CO)=NC(Cl)=C1O UPUKXPTXCGNQJR-UHFFFAOYSA-N 0.000 description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 62
- 238000010265 fast atom bombardment Methods 0.000 description 62
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 58
- 239000003921 oil Substances 0.000 description 57
- 235000019198 oils Nutrition 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 53
- 235000002639 sodium chloride Nutrition 0.000 description 51
- 239000013058 crude material Substances 0.000 description 50
- 239000010410 layer Substances 0.000 description 48
- 239000002253 acid Substances 0.000 description 43
- 230000000694 effects Effects 0.000 description 43
- 239000000706 filtrate Substances 0.000 description 43
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 40
- 239000000741 silica gel Substances 0.000 description 39
- 229910002027 silica gel Inorganic materials 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 35
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 34
- 239000002002 slurry Substances 0.000 description 33
- 239000003480 eluent Substances 0.000 description 31
- 239000011734 sodium Substances 0.000 description 31
- 229920006395 saturated elastomer Polymers 0.000 description 29
- 239000000725 suspension Substances 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 150000002431 hydrogen Chemical class 0.000 description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- 239000000377 silicon dioxide Substances 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- JYTYBRREMOCQHE-UHFFFAOYSA-N (7-chlorofuro[2,3-c]pyridin-5-yl)methanol Chemical compound ClC1=NC(CO)=CC2=C1OC=C2 JYTYBRREMOCQHE-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 13
- 229960002715 nicotine Drugs 0.000 description 13
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 208000010877 cognitive disease Diseases 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 239000008177 pharmaceutical agent Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000011630 iodine Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 235000011089 carbon dioxide Nutrition 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 229940005529 antipsychotics Drugs 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 208000027061 mild cognitive impairment Diseases 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 230000000698 schizophrenic effect Effects 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000003039 volatile agent Substances 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 206010012239 Delusion Diseases 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 230000000561 anti-psychotic effect Effects 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 239000003693 atypical antipsychotic agent Substances 0.000 description 5
- 229940127236 atypical antipsychotics Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 230000001713 cholinergic effect Effects 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 231100000868 delusion Toxicity 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000010502 orange oil Substances 0.000 description 5
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 4
- ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 description 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N 2,4-Dimethylpyridine Chemical compound CC1=CC=NC(C)=C1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 4
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 208000004547 Hallucinations Diseases 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 208000021017 Weight Gain Diseases 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 239000010779 crude oil Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 206010013663 drug dependence Diseases 0.000 description 4
- ZZEHSWOSYCXPIE-UHFFFAOYSA-N ethyl 3-hydroxyfuro[2,3-b]pyridine-2-carboxylate Chemical compound C1=CC=C2C(O)=C(C(=O)OCC)OC2=N1 ZZEHSWOSYCXPIE-UHFFFAOYSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- IZLZCXOWFDCZLD-UHFFFAOYSA-N furo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2OC(C(=O)O)=CC2=C1 IZLZCXOWFDCZLD-UHFFFAOYSA-N 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 4
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 230000009151 sensory gating Effects 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 208000011117 substance-related disease Diseases 0.000 description 4
- CXLPUYICXYYVRE-UHFFFAOYSA-N (2-methylfuro[2,3-c]pyridin-5-yl)methanol Chemical compound OCC1=NC=C2OC(C)=CC2=C1 CXLPUYICXYYVRE-UHFFFAOYSA-N 0.000 description 3
- VJENICOVWOKEGT-UHFFFAOYSA-N (2-trimethylsilylfuro[2,3-c]pyridin-5-yl)methanol Chemical compound OCC1=NC=C2OC([Si](C)(C)C)=CC2=C1 VJENICOVWOKEGT-UHFFFAOYSA-N 0.000 description 3
- FFKPQRMZZJGVRU-UHFFFAOYSA-N (3-methyl-2,3-dihydrofuro[2,3-c]pyridin-5-yl)methanol Chemical compound N1=C(CO)C=C2C(C)COC2=C1 FFKPQRMZZJGVRU-UHFFFAOYSA-N 0.000 description 3
- PKUGOEKKIILFPA-UHFFFAOYSA-N (3-methyl-2,3-dihydrofuro[2,3-c]pyridin-5-yl)methyl acetate Chemical compound N1=C(COC(C)=O)C=C2C(C)COC2=C1 PKUGOEKKIILFPA-UHFFFAOYSA-N 0.000 description 3
- JIPATFUJPNFNLZ-UHFFFAOYSA-N (3-methylfuro[2,3-c]pyridin-5-yl)methanol Chemical compound N1=C(CO)C=C2C(C)=COC2=C1 JIPATFUJPNFNLZ-UHFFFAOYSA-N 0.000 description 3
- VJPCATMALHOQOZ-UHFFFAOYSA-N (7-chloro-2-methylfuro[2,3-c]pyridin-5-yl)methanol Chemical compound OCC1=NC(Cl)=C2OC(C)=CC2=C1 VJPCATMALHOQOZ-UHFFFAOYSA-N 0.000 description 3
- LBIISAARLQVUQA-UHFFFAOYSA-N (7-chloro-3,3-dimethyl-2h-furo[2,3-c]pyridin-5-yl)methanol Chemical compound C1=C(CO)N=C(Cl)C2=C1C(C)(C)CO2 LBIISAARLQVUQA-UHFFFAOYSA-N 0.000 description 3
- KINTZNBXMLSLNH-UHFFFAOYSA-N (7-chloro-3-methyl-2,3-dihydrofuro[2,3-c]pyridin-5-yl)methanol Chemical compound C1=C(CO)N=C(Cl)C2=C1C(C)CO2 KINTZNBXMLSLNH-UHFFFAOYSA-N 0.000 description 3
- WSWXGLJGQDOZOL-UHFFFAOYSA-N 2,3-dihydrofuro[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1OCC2 WSWXGLJGQDOZOL-UHFFFAOYSA-N 0.000 description 3
- RCOZSTKGYDPHJR-UHFFFAOYSA-N 2,6-dibromo-4-iodopyridin-3-ol Chemical compound OC1=C(I)C=C(Br)N=C1Br RCOZSTKGYDPHJR-UHFFFAOYSA-N 0.000 description 3
- RKOLKIWJSXSHLV-UHFFFAOYSA-N 2,6-dibromopyridin-3-ol Chemical compound OC1=CC=C(Br)N=C1Br RKOLKIWJSXSHLV-UHFFFAOYSA-N 0.000 description 3
- VOLZBNCSKJILIA-UHFFFAOYSA-N 2-(diethoxymethyl)furo[2,3-c]pyridine Chemical compound C1=NC=C2OC(C(OCC)OCC)=CC2=C1 VOLZBNCSKJILIA-UHFFFAOYSA-N 0.000 description 3
- PRVUTBMNNPPEEU-UHFFFAOYSA-N 2-(diethoxymethyl)furo[3,2-c]pyridine Chemical compound N1=CC=C2OC(C(OCC)OCC)=CC2=C1 PRVUTBMNNPPEEU-UHFFFAOYSA-N 0.000 description 3
- NQELPILICRHYOE-UHFFFAOYSA-N 2-chloro-6-(hydroxymethyl)pyridin-3-ol Chemical compound OCC1=CC=C(O)C(Cl)=N1 NQELPILICRHYOE-UHFFFAOYSA-N 0.000 description 3
- KHPAGGHFIDLUMB-UHFFFAOYSA-N 2-chloropyridine-3-carbaldehyde Chemical compound ClC1=NC=CC=C1C=O KHPAGGHFIDLUMB-UHFFFAOYSA-N 0.000 description 3
- IOVCQYVRHJGXFE-UHFFFAOYSA-N 2-methylfuro[2,3-c]pyridine-5-carbaldehyde Chemical compound O=CC1=NC=C2OC(C)=CC2=C1 IOVCQYVRHJGXFE-UHFFFAOYSA-N 0.000 description 3
- IMQBZSJLELBSRO-UHFFFAOYSA-N 3,3-dimethyl-2h-furo[2,3-c]pyridine-5-carbaldehyde Chemical compound N1=C(C=O)C=C2C(C)(C)COC2=C1 IMQBZSJLELBSRO-UHFFFAOYSA-N 0.000 description 3
- JPPLSMNLMJCFBS-UHFFFAOYSA-N 3-methylfuro[2,3-c]pyridine-5-carbaldehyde Chemical compound N1=C(C=O)C=C2C(C)=COC2=C1 JPPLSMNLMJCFBS-UHFFFAOYSA-N 0.000 description 3
- BBCPUHYBMUPBIQ-UHFFFAOYSA-N 5,7-dibromo-2-(diethoxymethyl)furo[2,3-c]pyridine Chemical compound BrC1=NC(Br)=C2OC(C(OCC)OCC)=CC2=C1 BBCPUHYBMUPBIQ-UHFFFAOYSA-N 0.000 description 3
- QBZPLRCENXPNIR-UHFFFAOYSA-N 7-chlorofuro[2,3-c]pyridine-5-carbaldehyde Chemical compound ClC1=NC(C=O)=CC2=C1OC=C2 QBZPLRCENXPNIR-UHFFFAOYSA-N 0.000 description 3
- PXTZUYPPAYUOEY-UHFFFAOYSA-N 7-chlorofuro[2,3-c]pyridine-5-carboxylic acid Chemical compound ClC1=NC(C(=O)O)=CC2=C1OC=C2 PXTZUYPPAYUOEY-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010044688 Trisomy 21 Diseases 0.000 description 3
- GSTWPWWOLRJLFK-UHFFFAOYSA-N [6-chloro-4-iodo-5-(2-methylprop-2-enoxy)pyridin-2-yl]methanol Chemical compound CC(=C)COC1=C(Cl)N=C(CO)C=C1I GSTWPWWOLRJLFK-UHFFFAOYSA-N 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 208000013404 behavioral symptom Diseases 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical group CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 238000009225 cognitive behavioral therapy Methods 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- FRAKJSUXVQJONI-UHFFFAOYSA-N ethyl furo[2,3-b]pyridine-2-carboxylate Chemical compound C1=CN=C2OC(C(=O)OCC)=CC2=C1 FRAKJSUXVQJONI-UHFFFAOYSA-N 0.000 description 3
- 210000002196 fr. b Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- UUKNFBHTKFKPEH-UHFFFAOYSA-N furo[2,3-c]pyridin-5-ylmethanol Chemical compound C1=NC(CO)=CC2=C1OC=C2 UUKNFBHTKFKPEH-UHFFFAOYSA-N 0.000 description 3
- BEVAEUJOJMQCIU-UHFFFAOYSA-N furo[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1OC=C2 BEVAEUJOJMQCIU-UHFFFAOYSA-N 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000000181 nicotinic agonist Substances 0.000 description 3
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 229940018503 zyban Drugs 0.000 description 3
- IYWLMYXIUVLLGB-GAGWNIJNSA-N (2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CN2[C@@H](C)[C@H](N)C1CC2 IYWLMYXIUVLLGB-GAGWNIJNSA-N 0.000 description 2
- YMYMALDOJJGSNF-UHFFFAOYSA-N (3-bromofuro[2,3-c]pyridin-5-yl)methanol Chemical compound C1=NC(CO)=CC2=C1OC=C2Br YMYMALDOJJGSNF-UHFFFAOYSA-N 0.000 description 2
- IDBPUUNCAKIIQG-UHFFFAOYSA-N (3-chlorofuro[2,3-c]pyridin-5-yl)methanol Chemical compound C1=NC(CO)=CC2=C1OC=C2Cl IDBPUUNCAKIIQG-UHFFFAOYSA-N 0.000 description 2
- REUAXQZIRFXQML-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2[C@@H](N)CN1CC2 REUAXQZIRFXQML-ZETCQYMHSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- YSMXJEKOIIULPX-UHFFFAOYSA-N (6-chloro-4-iodo-5-prop-2-enoxypyridin-2-yl)methanol Chemical compound OCC1=CC(I)=C(OCC=C)C(Cl)=N1 YSMXJEKOIIULPX-UHFFFAOYSA-N 0.000 description 2
- MBNMGGKBGCIEGF-UHFFFAOYSA-N 1,1-diethoxypropane Chemical compound CCOC(CC)OCC MBNMGGKBGCIEGF-UHFFFAOYSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- CYXIMHJYXZWMFY-UHFFFAOYSA-N 1-benzofuran-2,3-dicarbaldehyde Chemical compound C1=CC=C2C(C=O)=C(C=O)OC2=C1 CYXIMHJYXZWMFY-UHFFFAOYSA-N 0.000 description 2
- JPYBOGFQEPDJRZ-UHFFFAOYSA-N 2,3-dibromo-1-benzofuran Chemical compound C1=CC=C2C(Br)=C(Br)OC2=C1 JPYBOGFQEPDJRZ-UHFFFAOYSA-N 0.000 description 2
- MOQKFCFVTVIJJS-UHFFFAOYSA-N 2,4-dimethyl-3-nitropyridine Chemical compound CC1=CC=NC(C)=C1[N+]([O-])=O MOQKFCFVTVIJJS-UHFFFAOYSA-N 0.000 description 2
- GMAJNANLBOHCAU-UHFFFAOYSA-N 2,4-dimethyl-5-nitropyridine Chemical compound CC1=CC(C)=C([N+]([O-])=O)C=N1 GMAJNANLBOHCAU-UHFFFAOYSA-N 0.000 description 2
- HVCYBWBFGOWBFT-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-1-benzofuran-3-carbaldehyde Chemical compound O1C2=CC=CC=C2C(C=O)=C1C1OCCO1 HVCYBWBFGOWBFT-UHFFFAOYSA-N 0.000 description 2
- CAGGLVAWUUHLEY-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)furan-3-carbaldehyde Chemical compound C1=COC(C2OCCO2)=C1C=O CAGGLVAWUUHLEY-UHFFFAOYSA-N 0.000 description 2
- CQSRCIILSKBLOI-UHFFFAOYSA-N 2-(3-bromofuran-2-yl)-1,3-dioxolane Chemical compound C1=COC(C2OCCO2)=C1Br CQSRCIILSKBLOI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QZHXIGDVIINLKX-UHFFFAOYSA-N 2-chloro-6-(hydroxymethyl)-4-iodopyridin-3-ol Chemical compound OCC1=CC(I)=C(O)C(Cl)=N1 QZHXIGDVIINLKX-UHFFFAOYSA-N 0.000 description 2
- HGMKWFMIOFOYOX-UHFFFAOYSA-N 2-formyl-3-methylbutanenitrile;sodium Chemical compound [Na].CC(C)C(C=O)C#N HGMKWFMIOFOYOX-UHFFFAOYSA-N 0.000 description 2
- LGOHLIRGPFPGKT-UHFFFAOYSA-N 2-methyl-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(C)C2=O LGOHLIRGPFPGKT-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- OQOINWAKHMHHTO-UHFFFAOYSA-N 2-methylfuro[2,3-c]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=NC=C2OC(C)=CC2=C1 OQOINWAKHMHHTO-UHFFFAOYSA-N 0.000 description 2
- JIZRGGUCOQKGQD-UHFFFAOYSA-N 2-nitrothiophene Chemical compound [O-][N+](=O)C1=CC=CS1 JIZRGGUCOQKGQD-UHFFFAOYSA-N 0.000 description 2
- NGLYQLOQMWMXAE-UHFFFAOYSA-N 3,3-dimethyl-2h-furo[2,3-c]pyridine-5-carboxylic acid Chemical compound N1=C(C(O)=O)C=C2C(C)(C)COC2=C1 NGLYQLOQMWMXAE-UHFFFAOYSA-N 0.000 description 2
- XJHLNJBEPAUFOD-UHFFFAOYSA-N 3-bromo-1-benzofuran-2-carbaldehyde Chemical compound C1=CC=C2C(Br)=C(C=O)OC2=C1 XJHLNJBEPAUFOD-UHFFFAOYSA-N 0.000 description 2
- KLDLDUZMQGWJEA-UHFFFAOYSA-N 3-bromo-2-(1,3-dioxolan-2-yl)-1-benzofuran Chemical compound O1C2=CC=CC=C2C(Br)=C1C1OCCO1 KLDLDUZMQGWJEA-UHFFFAOYSA-N 0.000 description 2
- KSAVZSUPQGDMRC-UHFFFAOYSA-N 3-bromofuran-2-carbaldehyde Chemical compound BrC=1C=COC=1C=O KSAVZSUPQGDMRC-UHFFFAOYSA-N 0.000 description 2
- XHWIXTKKKHEZPY-UHFFFAOYSA-N 3-bromofuro[2,3-c]pyridine-5-carbaldehyde Chemical compound N1=C(C=O)C=C2C(Br)=COC2=C1 XHWIXTKKKHEZPY-UHFFFAOYSA-N 0.000 description 2
- SCNMZFUBMZMTFJ-UHFFFAOYSA-N 3-bromofuro[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1OC=C2Br SCNMZFUBMZMTFJ-UHFFFAOYSA-N 0.000 description 2
- MBHHSPMBFVERGP-UHFFFAOYSA-N 3-bromothieno[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1SC=C2Br MBHHSPMBFVERGP-UHFFFAOYSA-N 0.000 description 2
- NEXUNCTUUDERGR-UHFFFAOYSA-N 3-chloro-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=CC(Cl)=C1 NEXUNCTUUDERGR-UHFFFAOYSA-N 0.000 description 2
- IOMXAIPNIAPSER-UHFFFAOYSA-N 3-chlorofuro[2,3-c]pyridine-5-carbaldehyde Chemical compound N1=C(C=O)C=C2C(Cl)=COC2=C1 IOMXAIPNIAPSER-UHFFFAOYSA-N 0.000 description 2
- FEHRHXJVDIIVKO-UHFFFAOYSA-N 3-chlorofuro[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1OC=C2Cl FEHRHXJVDIIVKO-UHFFFAOYSA-N 0.000 description 2
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 206010001540 Akathisia Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000015592 Involuntary movements Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 description 2
- OQNIOUUSBNJXGH-UHFFFAOYSA-N [1]benzofuro[3,2-c]pyridine-3-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=C(C(=O)O)N=C2 OQNIOUUSBNJXGH-UHFFFAOYSA-N 0.000 description 2
- BYLMMOUGBBLSMY-UHFFFAOYSA-N [1]benzothiolo[2,3-c]pyridine-3-carboxylic acid Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(=O)O)=C2 BYLMMOUGBBLSMY-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000010482 emotional regulation Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- KEMHDISEJAEDNP-UHFFFAOYSA-N furo[3,2-c]pyridine-6-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1C=CO2 KEMHDISEJAEDNP-UHFFFAOYSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960000423 loxapine Drugs 0.000 description 2
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
- 229960000300 mesoridazine Drugs 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- HXPFPHOMAVLKKD-UHFFFAOYSA-N methyl 3-bromothieno[2,3-c]pyridine-5-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=C1SC=C2Br HXPFPHOMAVLKKD-UHFFFAOYSA-N 0.000 description 2
- OZVQPMGJPOWPNI-UHFFFAOYSA-N methyl [1]benzofuro[3,2-c]pyridine-3-carboxylate Chemical compound O1C2=CC=CC=C2C2=C1C=C(C(=O)OC)N=C2 OZVQPMGJPOWPNI-UHFFFAOYSA-N 0.000 description 2
- OMAYNBSQUIYKJC-UHFFFAOYSA-N methyl [1]benzothiolo[2,3-c]pyridine-3-carboxylate Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(=O)OC)=C2 OMAYNBSQUIYKJC-UHFFFAOYSA-N 0.000 description 2
- RNBGAXVXEPGWIB-UHFFFAOYSA-N methyl [1]benzothiolo[3,2-c]pyridine-3-carboxylate Chemical compound S1C2=CC=CC=C2C2=C1C=C(C(=O)OC)N=C2 RNBGAXVXEPGWIB-UHFFFAOYSA-N 0.000 description 2
- ZFCLYJSFOBGLFF-UHFFFAOYSA-N methyl furo[3,2-c]pyridine-6-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=C1C=CO2 ZFCLYJSFOBGLFF-UHFFFAOYSA-N 0.000 description 2
- KQQNBNAMXWPKGP-UHFFFAOYSA-N methyl thieno[3,2-c]pyridine-6-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=C1C=CS2 KQQNBNAMXWPKGP-UHFFFAOYSA-N 0.000 description 2
- OAVYDSCRGZINNE-UHFFFAOYSA-N methyl thieno[3,4-c]pyridine-6-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=CSC=C21 OAVYDSCRGZINNE-UHFFFAOYSA-N 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960004938 molindone Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
- ALCVTORFSPUAIE-BUXKBTBVSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[3,2-c]pyridine-3-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C1=CC=CC=C1O2 ALCVTORFSPUAIE-BUXKBTBVSA-N 0.000 description 2
- NQVVSGZEDRARRL-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CN=CC=C2O1 NQVVSGZEDRARRL-BONVTDFDSA-N 0.000 description 2
- QWFQDKXPJZVKNV-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-dihydrofuro[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OCC2 QWFQDKXPJZVKNV-GXKRWWSZSA-N 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000007425 progressive decline Effects 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- FPXVLCLVAIUGPW-UHFFFAOYSA-N pyridin-3-ylmethyl acetate Chemical compound CC(=O)OCC1=CC=CN=C1 FPXVLCLVAIUGPW-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- CDAPZSKCTPHSJW-UHFFFAOYSA-N thieno[3,4-c]pyridine-6-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=CSC=C21 CDAPZSKCTPHSJW-UHFFFAOYSA-N 0.000 description 2
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical compound NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 description 2
- GCYSRLXIEWTZNM-UHFFFAOYSA-N thiophene-3,4-dicarbaldehyde Chemical compound O=CC1=CSC=C1C=O GCYSRLXIEWTZNM-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 125000005500 uronium group Chemical group 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- NIBLFQFBAYHCQS-XPUUQOCRSA-N (2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CN2[C@@H](C)[C@H](N)C1CC2 NIBLFQFBAYHCQS-XPUUQOCRSA-N 0.000 description 1
- ATOORYZBTGJGEL-UHFFFAOYSA-N (3,3-dimethyl-2h-furo[2,3-c]pyridin-5-yl)methanol Chemical compound N1=C(CO)C=C2C(C)(C)COC2=C1 ATOORYZBTGJGEL-UHFFFAOYSA-N 0.000 description 1
- STZHBULOYDCZET-KLXURFKVSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CC2[C@@H](N)CN1CC2 STZHBULOYDCZET-KLXURFKVSA-N 0.000 description 1
- REUAXQZIRFXQML-SSDOTTSWSA-N (3s)-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2[C@H](N)CN1CC2 REUAXQZIRFXQML-SSDOTTSWSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- IIPJFASIZVDONL-UHFFFAOYSA-N (7-chloro-2-trimethylsilylfuro[2,3-c]pyridin-5-yl)methanol Chemical compound OCC1=NC(Cl)=C2OC([Si](C)(C)C)=CC2=C1 IIPJFASIZVDONL-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 1
- STZHBULOYDCZET-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine;hydron;dichloride Chemical compound Cl.Cl.C1CC2C(N)CN1CC2 STZHBULOYDCZET-UHFFFAOYSA-N 0.000 description 1
- OZCJTNLELXWUTQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octane-2-carboxamide Chemical compound C1CN2C(C(=O)N)CC1CC2 OZCJTNLELXWUTQ-UHFFFAOYSA-N 0.000 description 1
- VTZUYVQTGCJXFL-UHFFFAOYSA-N 1-benzothiophene-2,3-dicarbaldehyde Chemical compound C1=CC=C2C(C=O)=C(C=O)SC2=C1 VTZUYVQTGCJXFL-UHFFFAOYSA-N 0.000 description 1
- JKXQKGNGJVZKFA-UHFFFAOYSA-N 1-chloro-3-methylbut-2-ene Chemical compound CC(C)=CCCl JKXQKGNGJVZKFA-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- MAFSLBPTVMXOIN-UHFFFAOYSA-N 1-methylpyrrolo[2,3-c]pyridine-5-carbaldehyde Chemical compound O=CC1=NC=C2N(C)C=CC2=C1 MAFSLBPTVMXOIN-UHFFFAOYSA-N 0.000 description 1
- OZJHMIHJOVLYDQ-UHFFFAOYSA-N 1-methylpyrrolo[2,3-c]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=NC=C2N(C)C=CC2=C1 OZJHMIHJOVLYDQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SHTJIHCOCNIHLP-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine-5-carbaldehyde Chemical compound C1=NC(C=O)=CC2=C1NC=C2 SHTJIHCOCNIHLP-UHFFFAOYSA-N 0.000 description 1
- GMCCMHXRFLJCMC-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1NC=C2 GMCCMHXRFLJCMC-UHFFFAOYSA-N 0.000 description 1
- MRUJSTYNKVSMNY-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-4-methyl-5-nitropyridine Chemical compound C1=C([N+]([O-])=O)C(C)=CC(C2OCCO2)=N1 MRUJSTYNKVSMNY-UHFFFAOYSA-N 0.000 description 1
- VRHJBWUIWQOFLF-WLHGVMLRSA-N 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 VRHJBWUIWQOFLF-WLHGVMLRSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- YKHQFTANTNMYPP-UHFFFAOYSA-N 2-bromopyridin-3-ol Chemical compound OC1=CC=CN=C1Br YKHQFTANTNMYPP-UHFFFAOYSA-N 0.000 description 1
- RSOPTYAZDFSMTN-UHFFFAOYSA-N 2-chloropyridin-3-ol Chemical compound OC1=CC=CN=C1Cl RSOPTYAZDFSMTN-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- WBMMJHMFZQJKNC-UHFFFAOYSA-N 2-formyl-3-methylbutanenitrile Chemical compound CC(C)C(C=O)C#N WBMMJHMFZQJKNC-UHFFFAOYSA-N 0.000 description 1
- IKCQWKJZLSDDSS-UHFFFAOYSA-N 2-formyloxyethyl formate Chemical compound O=COCCOC=O IKCQWKJZLSDDSS-UHFFFAOYSA-N 0.000 description 1
- JQEZLSUFDXSIEK-UHFFFAOYSA-N 2-hydroxy-2-(phenylmethoxycarbonylamino)acetic acid Chemical compound OC(=O)C(O)NC(=O)OCC1=CC=CC=C1 JQEZLSUFDXSIEK-UHFFFAOYSA-N 0.000 description 1
- NHPWIWAGVOXDPU-UHFFFAOYSA-N 2-methylidene-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(=C)C2=O NHPWIWAGVOXDPU-UHFFFAOYSA-N 0.000 description 1
- WGTNAUBLJLWMAP-UHFFFAOYSA-N 2-methylidene-1-azabicyclo[2.2.2]octan-3-one;dihydrate;hydrochloride Chemical compound O.O.Cl.C1CC2CCN1C(=C)C2=O WGTNAUBLJLWMAP-UHFFFAOYSA-N 0.000 description 1
- ZEHZWIKRZOLNDL-UHFFFAOYSA-N 2h-thieno[2,3-c]pyridine-6-carboxylic acid Chemical compound OC(=O)N1C=CC2=CCSC2=C1 ZEHZWIKRZOLNDL-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SRWDQSRTOOMPMO-UHFFFAOYSA-N 3-bromo-1-benzothiophene Chemical compound C1=CC=C2C(Br)=CSC2=C1 SRWDQSRTOOMPMO-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- LXWLEQZDXOQZGW-UHFFFAOYSA-N 3-bromofuran Chemical compound BrC=1C=COC=1 LXWLEQZDXOQZGW-UHFFFAOYSA-N 0.000 description 1
- YDPLFBIGFQFIDB-UHFFFAOYSA-N 3-chloropyridine-2-carbonitrile Chemical compound ClC1=CC=CN=C1C#N YDPLFBIGFQFIDB-UHFFFAOYSA-N 0.000 description 1
- ZVGDKOQPJCOCLI-UHFFFAOYSA-N 3-chloropyridine-4-carbaldehyde Chemical compound ClC1=CN=CC=C1C=O ZVGDKOQPJCOCLI-UHFFFAOYSA-N 0.000 description 1
- GXWYGAIVEGCARB-UHFFFAOYSA-N 3-ethylfuro[2,3-c]pyridine-5-carboxylic acid Chemical compound N1=C(C(O)=O)C=C2C(CC)=COC2=C1 GXWYGAIVEGCARB-UHFFFAOYSA-N 0.000 description 1
- YMAIMLIFWHAIKB-UHFFFAOYSA-N 3-iodo-1h-pyridin-4-one Chemical compound IC1=CNC=CC1=O YMAIMLIFWHAIKB-UHFFFAOYSA-N 0.000 description 1
- GFMQGLPLXYLYJC-VFZGTOFNSA-N 3-iodo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2I GFMQGLPLXYLYJC-VFZGTOFNSA-N 0.000 description 1
- JKHZOVOHNKSEQG-UHFFFAOYSA-N 3-methylfuro[2,3-c]pyridine-5-carboxylic acid Chemical compound N1=C(C(O)=O)C=C2C(C)=COC2=C1 JKHZOVOHNKSEQG-UHFFFAOYSA-N 0.000 description 1
- UYBOQGYUHATTJC-UHFFFAOYSA-N 3-propan-2-ylfuro[2,3-c]pyridine-5-carboxylic acid Chemical compound N1=C(C(O)=O)C=C2C(C(C)C)=COC2=C1 UYBOQGYUHATTJC-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- DYRMBQRXOMOMNW-UHFFFAOYSA-N 4-chloropyridine-3-carbaldehyde Chemical compound ClC1=CC=NC=C1C=O DYRMBQRXOMOMNW-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- OBGLQHSGHQAMLV-UHFFFAOYSA-N 4-methyl-5-nitropyridine-2-carbaldehyde Chemical compound CC1=CC(C=O)=NC=C1[N+]([O-])=O OBGLQHSGHQAMLV-UHFFFAOYSA-N 0.000 description 1
- KXOAVWGIMVAJIO-UHFFFAOYSA-N 5-(1,3-dioxolan-2-yl)-1-methylpyrrolo[2,3-c]pyridine Chemical compound N=1C=C2N(C)C=CC2=CC=1C1OCCO1 KXOAVWGIMVAJIO-UHFFFAOYSA-N 0.000 description 1
- SIKGOTOOCJGJQO-UHFFFAOYSA-N 5-(1,3-dioxolan-2-yl)-1h-pyrrolo[2,3-c]pyridine Chemical compound O1CCOC1C(N=C1)=CC2=C1NC=C2 SIKGOTOOCJGJQO-UHFFFAOYSA-N 0.000 description 1
- 102100024954 5-hydroxytryptamine receptor 3A Human genes 0.000 description 1
- SDRZCVDIDNFMAD-UHFFFAOYSA-N 7-oxidothieno[2,3-b]pyridin-7-ium Chemical compound [O-][N+]1=CC=CC2=C1SC=C2 SDRZCVDIDNFMAD-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101000783401 Bungarus multicinctus Alpha-bungarotoxin Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 1
- 102100024452 DNA-directed RNA polymerase III subunit RPC1 Human genes 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000689002 Homo sapiens DNA-directed RNA polymerase III subunit RPC1 Proteins 0.000 description 1
- 101150045775 Htr3a gene Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 101100113998 Mus musculus Cnbd2 gene Proteins 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 208000018526 Narcotic-Related disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000008234 Tics Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- PLHUEBQIRPSUAH-UHFFFAOYSA-N [Cl].O=C1OCCN1P(O)(=O)N1C(OCC1)=O Chemical compound [Cl].O=C1OCCN1P(O)(=O)N1C(OCC1)=O PLHUEBQIRPSUAH-UHFFFAOYSA-N 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 1
- OTABRXUCCNVFEN-UHFFFAOYSA-N acetic acid;triphenylphosphane Chemical compound CC(O)=O.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 OTABRXUCCNVFEN-UHFFFAOYSA-N 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- 108020000715 acetylcholine receptors Proteins 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- XZSMZRXAEFNJCU-UHFFFAOYSA-N carfenazine Chemical compound C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 XZSMZRXAEFNJCU-UHFFFAOYSA-N 0.000 description 1
- 229950009852 carfenazine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- YTKRILODNOEEPX-NSCUHMNNSA-N crotyl chloride Chemical compound C\C=C\CCl YTKRILODNOEEPX-NSCUHMNNSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- CCVPHUGQSNUIBB-UHFFFAOYSA-N dimethoxyphosphoryl acetate Chemical compound COP(=O)(OC)OC(C)=O CCVPHUGQSNUIBB-UHFFFAOYSA-N 0.000 description 1
- MKYNHKOAYQRSBD-UHFFFAOYSA-N dioxouranium;nitric acid Chemical compound O=[U]=O.O[N+]([O-])=O.O[N+]([O-])=O MKYNHKOAYQRSBD-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- PMIMPBYTPPRBGD-UHFFFAOYSA-N ethyl 2-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1Cl PMIMPBYTPPRBGD-UHFFFAOYSA-N 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- MWUNMDKVCFRJPU-UHFFFAOYSA-N ethyl thieno[2,3-c]pyridine-2-carboxylate Chemical compound C1=NC=C2SC(C(=O)OCC)=CC2=C1 MWUNMDKVCFRJPU-UHFFFAOYSA-N 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- AHIXHWRUDZFHEZ-UHFFFAOYSA-N furan-2,3-dicarbaldehyde Chemical compound O=CC=1C=COC=1C=O AHIXHWRUDZFHEZ-UHFFFAOYSA-N 0.000 description 1
- CLJVRBPUNWKPKT-UHFFFAOYSA-N furo[2,3-c]pyridin-5-ylmethyl acetate Chemical compound C1=NC(COC(=O)C)=CC2=C1OC=C2 CLJVRBPUNWKPKT-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 102000006239 metabotropic receptors Human genes 0.000 description 1
- 108020004083 metabotropic receptors Proteins 0.000 description 1
- MXNIODZSMNMILW-UHFFFAOYSA-N methyl 2-acetamido-2-dimethoxyphosphorylacetate Chemical compound COC(=O)C(NC(C)=O)P(=O)(OC)OC MXNIODZSMNMILW-UHFFFAOYSA-N 0.000 description 1
- NNBQAZBSJUATDO-UHFFFAOYSA-N methyl 2-methoxy-2-(phenylmethoxycarbonylamino)acetate Chemical compound COC(=O)C(OC)NC(=O)OCC1=CC=CC=C1 NNBQAZBSJUATDO-UHFFFAOYSA-N 0.000 description 1
- FFHLOZJKPAWEAX-UHFFFAOYSA-N methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate Chemical compound C1=CN=C2C(N)=C(C(=O)OC)SC2=C1 FFHLOZJKPAWEAX-UHFFFAOYSA-N 0.000 description 1
- TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 1
- SUHXBEISAFXKIN-UHFFFAOYSA-N methyl thieno[2,3-b]pyridine-2-carboxylate Chemical compound C1=CN=C2SC(C(=O)OC)=CC2=C1 SUHXBEISAFXKIN-UHFFFAOYSA-N 0.000 description 1
- UJWDXLCZHGRIDS-UHFFFAOYSA-N methyl thieno[2,3-c]pyridine-5-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=C1SC=C2 UJWDXLCZHGRIDS-UHFFFAOYSA-N 0.000 description 1
- QIDGNOLDYYRKHI-UHFFFAOYSA-N methyl thieno[3,2-b]pyridine-2-carboxylate Chemical compound C1=CC=C2SC(C(=O)OC)=CC2=N1 QIDGNOLDYYRKHI-UHFFFAOYSA-N 0.000 description 1
- HAAMRBSFJYFWFW-UHFFFAOYSA-N methyl thieno[3,2-c]pyridine-2-carboxylate Chemical compound N1=CC=C2SC(C(=O)OC)=CC2=C1 HAAMRBSFJYFWFW-UHFFFAOYSA-N 0.000 description 1
- XLTANAWLDBYGFU-VTLKBQQISA-N methyllycaconitine Chemical compound C([C@]12CN([C@@H]3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)C[C@H](C)C1=O XLTANAWLDBYGFU-VTLKBQQISA-N 0.000 description 1
- FRZAEBZEHFXWKR-UHFFFAOYSA-N methyllycaconitine Natural products CCN1CC2(COC(=O)c3ccccc3N4C(=O)CC(C)C4=O)CCC(O)C56C7CC8C(O)C7C(O)(CC8OC)C(O)(C(OC)C25)C16 FRZAEBZEHFXWKR-UHFFFAOYSA-N 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- QYQZCDBKJWOCGE-UHFFFAOYSA-N n-(2-methyl-1-azabicyclo[2.2.2]octan-3-ylidene)hydroxylamine;hydrochloride Chemical compound Cl.C1CC2CCN1C(C)C2=NO QYQZCDBKJWOCGE-UHFFFAOYSA-N 0.000 description 1
- MQUIWJKZMYUCHV-RZSRGUMRSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2 MQUIWJKZMYUCHV-RZSRGUMRSA-N 0.000 description 1
- SZCUXTZRWDJLQZ-HZMBPMFUSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CC=CN=C2S1 SZCUXTZRWDJLQZ-HZMBPMFUSA-N 0.000 description 1
- DMNYGUNYKRIPCH-RZSRGUMRSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2 DMNYGUNYKRIPCH-RZSRGUMRSA-N 0.000 description 1
- OOCVKYKGQZMGGJ-UTLKBRERSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1-methylpyrrolo[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2N(C)C=CC2=C1 OOCVKYKGQZMGGJ-UTLKBRERSA-N 0.000 description 1
- VGEVNMXTLFLCFL-UTLKBRERSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrrolo[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1NC=C2 VGEVNMXTLFLCFL-UTLKBRERSA-N 0.000 description 1
- AHGFSCYLKOGUFF-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-(trifluoromethyl)furo[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C(F)(F)F)OC2=C1 AHGFSCYLKOGUFF-LBPRGKRZSA-N 0.000 description 1
- STVRGPITIYDSIK-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethenylfuro[3,2-c]pyridine-6-carboxamide Chemical class C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C=C)OC2=C1 STVRGPITIYDSIK-HNNXBMFYSA-N 0.000 description 1
- SZHQYGAJWICVNQ-UTLKBRERSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C(OC(C)=C2)C2=C1 SZHQYGAJWICVNQ-UTLKBRERSA-N 0.000 description 1
- CAISWDUMNFTYIT-UTLKBRERSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3,3-dimethyl-2h-furo[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OCC(C)(C)C2=C1 CAISWDUMNFTYIT-UTLKBRERSA-N 0.000 description 1
- HCIMHXKNJAXTRA-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(Cl)C2=C1 HCIMHXKNJAXTRA-GXKRWWSZSA-N 0.000 description 1
- MCFKPMVTHBYQRP-CKUXDGONSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(CC)C2=C1 MCFKPMVTHBYQRP-CKUXDGONSA-N 0.000 description 1
- HBKBYUHWEDDTDO-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-sulfanylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(S)C2=C1 HBKBYUHWEDDTDO-LBPRGKRZSA-N 0.000 description 1
- JWJPSSUTOXBRQZ-YDALLXLXSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chlorofuro[2,3-c]pyridine-5-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@H]1NC(=O)C(N=C1Cl)=CC2=C1OC=C2 JWJPSSUTOXBRQZ-YDALLXLXSA-N 0.000 description 1
- HDNYLRCTIAPHQO-SQKCAUCHSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[2,3-c]pyridine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.S1C2=CC=CC=C2C2=C1C=NC(C(N[C@@H]1C3CCN(CC3)C1)=O)=C2 HDNYLRCTIAPHQO-SQKCAUCHSA-N 0.000 description 1
- IXVDQMJJPAKIQK-SQKCAUCHSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[3,2-c]pyridine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.S1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@@H]1C(CC2)CCN2C1 IXVDQMJJPAKIQK-SQKCAUCHSA-N 0.000 description 1
- WDCJGTXNJRXGLG-YDALLXLXSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-b]pyridine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CN=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 WDCJGTXNJRXGLG-YDALLXLXSA-N 0.000 description 1
- BCVPFWBLDNBXIZ-LTCKWSDVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=NC=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 BCVPFWBLDNBXIZ-LTCKWSDVSA-N 0.000 description 1
- USJDQOUQSDDWPO-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2 USJDQOUQSDDWPO-GXKRWWSZSA-N 0.000 description 1
- OMRGYXZLDCEQNT-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CO2 OMRGYXZLDCEQNT-GXKRWWSZSA-N 0.000 description 1
- VDBSXNXZYUJSSU-LTCKWSDVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CN=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 VDBSXNXZYUJSSU-LTCKWSDVSA-N 0.000 description 1
- LUCHYNKYXTVXEW-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.N1=C2SC=CC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 LUCHYNKYXTVXEW-GXKRWWSZSA-N 0.000 description 1
- XBLCZLXVAZGAGA-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-6-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=C2C=CSC2=NC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 XBLCZLXVAZGAGA-GXKRWWSZSA-N 0.000 description 1
- CAHJRPJEJDNZAB-LTCKWSDVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=NC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 CAHJRPJEJDNZAB-LTCKWSDVSA-N 0.000 description 1
- BJPXADWQFUMLMW-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2 BJPXADWQFUMLMW-GXKRWWSZSA-N 0.000 description 1
- FHQWTDOVYZRKCI-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=C2SC=CC2=NC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 FHQWTDOVYZRKCI-GXKRWWSZSA-N 0.000 description 1
- SRPUSEIANCVFHQ-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-6-carboxamide;dihydrochloride Chemical compound Cl.Cl.N1=C2C=CSC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 SRPUSEIANCVFHQ-GXKRWWSZSA-N 0.000 description 1
- NRSQSZUDBNWUOY-LTCKWSDVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N1=CC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 NRSQSZUDBNWUOY-LTCKWSDVSA-N 0.000 description 1
- GOFNNDAVSYYGLF-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CS2 GOFNNDAVSYYGLF-GXKRWWSZSA-N 0.000 description 1
- BCKKMCXDLFONPN-UQKRIMTDSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,4-c]pyridine-6-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C2=CSC=C2C=NC=1C(=O)N[C@@H]1C(CC2)CCN2C1 BCKKMCXDLFONPN-UQKRIMTDSA-N 0.000 description 1
- RPAQKNMPMUTPBE-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3,3-dimethyl-2h-furo[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OCC(C)(C)C2=C1 RPAQKNMPMUTPBE-CQSZACIVSA-N 0.000 description 1
- GTPGKSNYGZTLQJ-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 GTPGKSNYGZTLQJ-GFCCVEGCSA-N 0.000 description 1
- ODXYAIIKLLODAU-UHFFFAOYSA-N n-octan-3-ylidenehydroxylamine Chemical compound CCCCCC(CC)=NO ODXYAIIKLLODAU-UHFFFAOYSA-N 0.000 description 1
- YLPYBBMTIYPKDC-UHFFFAOYSA-N n-octan-3-ylidenehydroxylamine;hydrochloride Chemical compound Cl.CCCCCC(CC)=NO YLPYBBMTIYPKDC-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000007107 neurocognitive deficit Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- LHLRIVKZRMTHAH-UHFFFAOYSA-N nitroso 2-methylpropanoate Chemical compound CC(C)C(=O)ON=O LHLRIVKZRMTHAH-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- OUSJHHILXRLTDF-UHFFFAOYSA-N octan-3-amine;dihydrochloride Chemical compound Cl.Cl.CCCCCC(N)CC OUSJHHILXRLTDF-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- XBLAYFVCUPTTOI-UHFFFAOYSA-N oxalic acid;thiophen-3-amine Chemical compound NC=1C=CSC=1.OC(=O)C(O)=O XBLAYFVCUPTTOI-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- FHPZOWOEILXXBD-UHFFFAOYSA-N phenylseleninyl benzeneseleninate Chemical compound C=1C=CC=CC=1[Se](=O)O[Se](=O)C1=CC=CC=C1 FHPZOWOEILXXBD-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 108020001213 potassium channel Chemical group 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- 230000003461 thalamocortical effect Effects 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 1
- XGCSHAYMNOFFNA-UHFFFAOYSA-N thieno[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2SC(C(=O)O)=CC2=C1 XGCSHAYMNOFFNA-UHFFFAOYSA-N 0.000 description 1
- IOVJNINZHOJSDD-UHFFFAOYSA-N thieno[2,3-b]pyridine-5-carbonitrile Chemical compound N#CC1=CN=C2SC=CC2=C1 IOVJNINZHOJSDD-UHFFFAOYSA-N 0.000 description 1
- JDWFURAFRCAVOH-UHFFFAOYSA-N thieno[2,3-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C2SC=CC2=C1 JDWFURAFRCAVOH-UHFFFAOYSA-N 0.000 description 1
- KTSOZLHVFLYDNN-UHFFFAOYSA-N thieno[2,3-b]pyridine-6-carbonitrile Chemical compound N#CC1=CC=C2C=CSC2=N1 KTSOZLHVFLYDNN-UHFFFAOYSA-N 0.000 description 1
- MJUWERVDNLIFQL-UHFFFAOYSA-N thieno[2,3-b]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CSC2=N1 MJUWERVDNLIFQL-UHFFFAOYSA-N 0.000 description 1
- GHYPQAOXZUEFNP-UHFFFAOYSA-N thieno[2,3-c]pyridine-2-carboxylic acid Chemical compound C1=NC=C2SC(C(=O)O)=CC2=C1 GHYPQAOXZUEFNP-UHFFFAOYSA-N 0.000 description 1
- RIIAHEIBOHZBED-UHFFFAOYSA-N thieno[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1SC=C2 RIIAHEIBOHZBED-UHFFFAOYSA-N 0.000 description 1
- WVWCTPQHJWMLKI-UHFFFAOYSA-N thieno[3,2-b]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=N1 WVWCTPQHJWMLKI-UHFFFAOYSA-N 0.000 description 1
- CWBYTSQAVGCXFW-UHFFFAOYSA-N thieno[3,2-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2SC=CC2=N1 CWBYTSQAVGCXFW-UHFFFAOYSA-N 0.000 description 1
- QYCIXUKZMDUDBK-UHFFFAOYSA-N thieno[3,2-b]pyridine-6-carbonitrile Chemical compound N#CC1=CN=C2C=CSC2=C1 QYCIXUKZMDUDBK-UHFFFAOYSA-N 0.000 description 1
- WEYMRIJRWNCSFV-UHFFFAOYSA-N thieno[3,2-b]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN=C2C=CSC2=C1 WEYMRIJRWNCSFV-UHFFFAOYSA-N 0.000 description 1
- VKOINCMQZKBKHH-UHFFFAOYSA-N thieno[3,2-c]pyridine-2-carboxylic acid Chemical compound N1=CC=C2SC(C(=O)O)=CC2=C1 VKOINCMQZKBKHH-UHFFFAOYSA-N 0.000 description 1
- SJOJSVUJOMBMRX-UHFFFAOYSA-N thieno[3,2-c]pyridine-6-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1C=CS2 SJOJSVUJOMBMRX-UHFFFAOYSA-N 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- JSLBLMYJYPZTEB-UHFFFAOYSA-N thiophene-3,4-dicarbonitrile Chemical compound N#CC1=CSC=C1C#N JSLBLMYJYPZTEB-UHFFFAOYSA-N 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- ULYLMHUHFUQKOE-UHFFFAOYSA-N trimethyl(prop-2-ynyl)silane Chemical compound C[Si](C)(C)CC#C ULYLMHUHFUQKOE-UHFFFAOYSA-N 0.000 description 1
- JUDXOKKZTISQDJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 JUDXOKKZTISQDJ-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 229940039925 zyprexa Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29770801P | 2001-06-12 | 2001-06-12 | |
| US29771201P | 2001-06-12 | 2001-06-12 | |
| US29770901P | 2001-06-12 | 2001-06-12 | |
| US29771101P | 2001-06-12 | 2001-06-12 | |
| US29771001P | 2001-06-12 | 2001-06-12 | |
| US32859601P | 2001-10-11 | 2001-10-11 | |
| US37349502P | 2002-04-18 | 2002-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20033377A3 true CZ20033377A3 (cs) | 2004-11-10 |
Family
ID=27569623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20033377A CZ20033377A3 (cs) | 2001-06-12 | 2002-06-06 | Chinuklidinové sloučeniny substituované heterocykly s několika kruhy pro léčení chorob |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7067515B2 (enExample) |
| EP (1) | EP1406901A1 (enExample) |
| JP (1) | JP2004537532A (enExample) |
| KR (1) | KR20040018266A (enExample) |
| CN (1) | CN1511154A (enExample) |
| AR (1) | AR036040A1 (enExample) |
| BR (1) | BR0210384A (enExample) |
| CA (1) | CA2445467A1 (enExample) |
| CO (1) | CO5540302A2 (enExample) |
| CZ (1) | CZ20033377A3 (enExample) |
| EA (1) | EA200301216A1 (enExample) |
| IL (1) | IL159344A0 (enExample) |
| MX (1) | MXPA03011484A (enExample) |
| NO (1) | NO20035522D0 (enExample) |
| PE (1) | PE20030431A1 (enExample) |
| PL (1) | PL367311A1 (enExample) |
| WO (1) | WO2002100857A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911543B2 (en) * | 2001-10-02 | 2005-06-28 | Pfizer Inc. | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| DE10164139A1 (de) * | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US7977485B2 (en) | 2002-06-10 | 2011-07-12 | Bayer Schering Pharma Aktiengesellshaft | 2-heteroaryl carboxamides |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| CA2499128C (en) | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| WO2004039366A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| CA2503786A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases |
| OA12968A (en) * | 2002-12-06 | 2006-10-13 | Pharmacia & Upjohn Co Llc | Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof. |
| JP4598674B2 (ja) * | 2003-01-08 | 2010-12-15 | 田辺三菱製薬株式会社 | 統合失調症治療剤 |
| EP1587511A2 (en) * | 2003-01-22 | 2005-10-26 | Pharmacia & Upjohn Company LLC | Treatment of diseases with alpha-7 nach receptor full agonists |
| DE10334724A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| US7396833B2 (en) | 2003-12-22 | 2008-07-08 | Memory Pharmaceuticals Corporation | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| EP1699488A2 (en) * | 2003-12-23 | 2006-09-13 | Pfizer Products Incorporated | Therapeutic combination for cognition enhancement and psychotic disorders |
| US20050171079A1 (en) * | 2004-02-04 | 2005-08-04 | Schrimpf Michael R. | Amino-substituted tricyclic derivatives and methods of use |
| US7365193B2 (en) | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| CN103724343A (zh) | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
| CA2567977A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| KR20070015607A (ko) | 2004-05-07 | 2007-02-05 | 메모리 파마슈티칼스 코포레이션 | 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도 |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0424564D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| WO2006069097A2 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| WO2007027855A2 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2007038367A1 (en) * | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| RU2008139599A (ru) | 2006-03-07 | 2010-04-20 | Эррэй Биофарма Инк. (Us) | Гетеробициклические производные пиразола и способы их применения |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| US8697722B2 (en) * | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
| SI2889033T1 (en) | 2008-11-19 | 2018-08-31 | Forum Pharmaceuticals Inc. | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| WO2010132423A1 (en) * | 2009-05-11 | 2010-11-18 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
| WO2011020712A2 (en) * | 2009-08-18 | 2011-02-24 | Universite Libre De Bruxelles | Oligothiophenes derivatives |
| US8431595B2 (en) | 2009-08-20 | 2013-04-30 | The University Of Tennessee Research Foundation | Furanopyridine cannabinoid compounds and related methods of use |
| EP2523562B1 (en) * | 2010-01-11 | 2019-01-02 | Astraea Therapeutics, LLC | Nicotinic acetylcholine receptor modulators |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| KR101928505B1 (ko) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| EP2727604A4 (en) | 2011-06-30 | 2015-03-18 | Toray Industries | ANTIPRURIGINOUS AGENT |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| KR101684955B1 (ko) * | 2012-07-23 | 2016-12-12 | 주식회사유한양행 | 퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물 |
| JP6359940B2 (ja) * | 2014-10-14 | 2018-07-18 | 国立大学法人 名古屋工業大学 | ジフルオロメチルアセチレン化合物類及びその製造方法 |
| CN106883270B (zh) | 2015-11-26 | 2019-03-26 | 财团法人工业技术研究院 | 有机金属化合物、包含其的有机发光装置 |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| CN115974833B (zh) * | 2022-12-28 | 2024-08-02 | 苏州汉德创宏生化科技有限公司 | 一种3-氨基噻吩草酸盐的制备方法 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194747A (en) | 1979-08-29 | 1988-11-29 | Schering Ag | 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives |
| ZA832549B (en) | 1982-04-14 | 1988-09-28 | Beecham Group Plc | Pharmaceutically active compounds |
| FI74707C (fi) | 1982-06-29 | 1988-03-10 | Sandoz Ag | Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror. |
| DE3429830A1 (de) | 1983-08-26 | 1985-03-07 | Sandoz-Patent-GmbH, 7850 Lörrach | Automatische carbonsaeure- und sulfonsaeureester oder -amide |
| US5175173A (en) | 1983-12-22 | 1992-12-29 | Sun Jung Hui | Carboxamides useful as antiemetic or antipsychotic agents |
| US4888353A (en) | 1986-02-28 | 1989-12-19 | Erbamont, Inc. | Carboxamides useful as antiemetic or antipsychotic agents |
| DE3445377A1 (de) | 1983-12-23 | 1985-07-04 | Sandoz-Patent-GmbH, 7850 Lörrach | Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen |
| EP0385517B1 (en) | 1985-03-14 | 1993-04-14 | BEECHAM GROUP plc | Medicaments for the treatment of emesis |
| US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
| GB8520616D0 (en) | 1985-08-16 | 1985-09-25 | Beecham Group Plc | Compounds |
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| DE3782107T2 (de) | 1986-07-25 | 1993-04-01 | Beecham Group Plc | Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung. |
| HU202108B (en) | 1986-07-30 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol |
| EP0278173B1 (en) | 1986-12-17 | 1993-11-03 | Glaxo Group Limited | Use of heterocyclic derivatives in the treatment of depressions |
| EP0559297B1 (en) | 1986-12-17 | 1997-05-07 | Glaxo Group Limited | Use of heterocyclic derivatives for the manufacture of medicaments |
| GB8806990D0 (en) | 1988-03-23 | 1988-04-27 | Beecham Group Plc | Novel compounds |
| US5322951A (en) | 1987-01-05 | 1994-06-21 | Beecham Group, P.L.C. | Certain 1-(2,3-dihydro-indole)carbonyl intermediates |
| GB8701022D0 (en) | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| US4835162A (en) | 1987-02-12 | 1989-05-30 | Abood Leo G | Agonists and antagonists to nicotine as smoking deterents |
| DE3852145T2 (de) | 1987-02-18 | 1995-04-06 | Beecham Group Plc | Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten. |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US4921982A (en) | 1988-07-21 | 1990-05-01 | Eli Lilly And Company | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists |
| NZ227229A (en) | 1987-12-10 | 1991-03-26 | Duphar Int Res | Indole derivatives and pharmaceutical compositions |
| IE63474B1 (en) | 1987-12-24 | 1995-04-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| US4863919A (en) | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
| US4924010A (en) | 1988-02-04 | 1990-05-08 | Rorer Pharmaceutical Corporation | Benzoxepins as intermediates to 5HT3 antagonists |
| DE3810552A1 (de) | 1988-03-29 | 1989-10-19 | Sandoz Ag | Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben |
| US5246942A (en) | 1988-04-27 | 1993-09-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration |
| US4863921A (en) | 1988-04-27 | 1989-09-05 | Rorer Pharmaceutical Corporation | Dibenzofurancarboxamides and their pharmaceutical compositions and methods |
| US4920227A (en) | 1988-11-29 | 1990-04-24 | Rorer Pharmaceutical Corp. | Benzobicyclic carboxamide 5-HT3 antagonists |
| US4920219A (en) | 1988-11-29 | 1990-04-24 | Rorer Pharmaceutical Corp. | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents |
| US4933445A (en) | 1988-11-29 | 1990-06-12 | Rorer Pharmaceutical Corporation | Heteroazabenzobicyclic carboxamide 5-HT3 antagonists |
| WO1990014347A1 (fr) | 1989-05-24 | 1990-11-29 | Nippon Shinyaku Co., Ltd. | Derives d'indole et medicament |
| EP0402056A3 (en) | 1989-06-06 | 1991-09-04 | Beecham Group p.l.c. | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| US4935511A (en) | 1989-09-26 | 1990-06-19 | Rorer Pharmaceutical Corporation | Benzoxazine and benzoxazepine carboxamide 5-HT3 antagonists |
| GB2236751B (en) | 1989-10-14 | 1993-04-28 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| GB8928837D0 (en) | 1989-12-21 | 1990-02-28 | Beecham Group Plc | Pharmaceuticals |
| EP0436245A1 (en) | 1989-12-27 | 1991-07-10 | Duphar International Research B.V | Substituted 3,4-annelated benzimidazol-2(1H)-ones |
| GB9009542D0 (en) | 1990-04-27 | 1990-06-20 | Beecham Group Plc | Novel compounds |
| AU7618991A (en) | 1990-05-14 | 1991-11-14 | Syntex (U.S.A.) Inc. | Novel tricyclic compounds |
| AU8405891A (en) | 1990-08-31 | 1992-03-30 | Nippon Shinyaku Co. Ltd. | Indole derivative and medicine |
| US5200415A (en) * | 1990-11-01 | 1993-04-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives and their pharmaceutical use |
| US5189041A (en) | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
| GB9027098D0 (en) | 1990-12-13 | 1991-02-06 | Beecham Group Plc | Pharmaceuticals |
| HU211081B (en) | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| IL100432A (en) | 1990-12-27 | 1996-01-19 | Erba Carlo Spa | Dihydrobenzofuran carboxamide derivatives their preparation and pharmaceutical compositions containing them |
| US5114947A (en) | 1990-12-27 | 1992-05-19 | Erbamont Inc. | Method for alleviating anxiety using benzobicyclic carboxamides |
| GB9028105D0 (en) | 1990-12-27 | 1991-02-13 | Erba Carlo Spa | Process for the preparation of substituted benzofuran derivatives |
| US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
| DE4115215A1 (de) | 1991-05-10 | 1992-11-12 | Merck Patent Gmbh | Indolderivate |
| GB9120628D0 (en) | 1991-09-27 | 1991-11-06 | Fujisawa Pharmaceutical Co | Pyrrolobenzoxazine derivatives and process for preparation thereof |
| WO1993009116A1 (fr) * | 1991-11-07 | 1993-05-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose a base de quinuclidine et utilisation dudit compose en medecine |
| JPH05310732A (ja) | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| JP2699794B2 (ja) | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| US5273972A (en) | 1992-03-26 | 1993-12-28 | A. H. Robins Company, Incorporated | [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates |
| EP0635508B1 (en) * | 1992-04-10 | 1999-10-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Tetrahydropyridine derivative having substituents on three rings |
| SE9201478D0 (sv) | 1992-05-11 | 1992-05-11 | Kabi Pharmacia Ab | Heteroaromatic quinuclidinenes, their use and preparation |
| US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| US5977144A (en) | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| IT1265057B1 (it) * | 1993-08-05 | 1996-10-28 | Dompe Spa | Tropil 7-azaindolil-3-carbossiamidi |
| GB9406857D0 (en) | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5510478A (en) | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| GB9507882D0 (en) | 1995-04-18 | 1995-05-31 | Pharmacia Spa | Substituted dihydrobenzofuran derivatives as 5-ht4 agonists |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| ES2109190B1 (es) * | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
| FR2769915B1 (fr) | 1997-10-21 | 2000-10-13 | Synthelabo | Derives d'indazole tricycliques, leur preparation et leur application en therapeutique |
| JP2003501022A (ja) | 1999-05-27 | 2003-01-14 | ファルマシア・アンド・アップジョン・カンパニー | イオンチャネルコンダクタンスを測定するための方法およびその組成物 |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| JP4616971B2 (ja) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | １−アザビシクロアルカン化合物およびその医薬用途 |
| US20020016334A1 (en) | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| US6911543B2 (en) * | 2001-10-02 | 2005-06-28 | Pfizer Inc. | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| ES2348282T3 (es) | 2002-04-18 | 2010-12-02 | Astrazeneca Ab | Compuestos de tienilo. |
| MXPA04010191A (es) | 2002-04-18 | 2005-02-03 | Astrazeneca Ab | Compuestos de furilo. |
| BR0309345A (pt) | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa |
-
2002
- 2002-05-30 AR ARP020102020A patent/AR036040A1/es unknown
- 2002-06-05 PE PE2002000470A patent/PE20030431A1/es not_active Application Discontinuation
- 2002-06-06 IL IL15934402A patent/IL159344A0/xx unknown
- 2002-06-06 KR KR10-2003-7016210A patent/KR20040018266A/ko not_active Withdrawn
- 2002-06-06 CA CA002445467A patent/CA2445467A1/en not_active Abandoned
- 2002-06-06 CN CNA028098145A patent/CN1511154A/zh active Pending
- 2002-06-06 WO PCT/US2002/016568 patent/WO2002100857A1/en not_active Ceased
- 2002-06-06 EP EP02778932A patent/EP1406901A1/en not_active Withdrawn
- 2002-06-06 CZ CZ20033377A patent/CZ20033377A3/cs unknown
- 2002-06-06 BR BR0210384-2A patent/BR0210384A/pt not_active IP Right Cessation
- 2002-06-06 JP JP2003503624A patent/JP2004537532A/ja not_active Withdrawn
- 2002-06-06 PL PL02367311A patent/PL367311A1/xx not_active Application Discontinuation
- 2002-06-06 EA EA200301216A patent/EA200301216A1/ru unknown
- 2002-06-06 MX MXPA03011484A patent/MXPA03011484A/es unknown
- 2002-06-06 US US10/163,564 patent/US7067515B2/en not_active Expired - Fee Related
-
2003
- 2003-12-10 CO CO03108314A patent/CO5540302A2/es not_active Application Discontinuation
- 2003-12-11 NO NO20035522A patent/NO20035522D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2445467A1 (en) | 2002-12-19 |
| NO20035522D0 (no) | 2003-12-11 |
| WO2002100857A1 (en) | 2002-12-19 |
| PE20030431A1 (es) | 2003-05-26 |
| PL367311A1 (en) | 2005-02-21 |
| EP1406901A1 (en) | 2004-04-14 |
| US7067515B2 (en) | 2006-06-27 |
| IL159344A0 (en) | 2004-06-01 |
| AR036040A1 (es) | 2004-08-04 |
| EA200301216A1 (ru) | 2004-06-24 |
| US20030045540A1 (en) | 2003-03-06 |
| MXPA03011484A (es) | 2004-03-18 |
| CN1511154A (zh) | 2004-07-07 |
| KR20040018266A (ko) | 2004-03-02 |
| BR0210384A (pt) | 2004-06-29 |
| CO5540302A2 (es) | 2005-07-29 |
| JP2004537532A (ja) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ20033377A3 (cs) | Chinuklidinové sloučeniny substituované heterocykly s několika kruhy pro léčení chorob | |
| JP4371811B2 (ja) | 疾患治療のためのアザ二環式置換縮合ヘテロアリール化合物 | |
| EP1425286B1 (en) | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases | |
| US6828330B2 (en) | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | |
| JP6827959B2 (ja) | 三環式化合物およびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| MXPA04008038A (es) | Carboxamidas heteroaromaticas biciclicas condensadas con puente de n para el tratamiento de enfermedades. | |
| JP2005525357A (ja) | α７ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物 | |
| US6849620B2 (en) | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | |
| JP2005511574A6 (ja) | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド | |
| JP2005511574A (ja) | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド | |
| WO2004052894A1 (en) | Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof | |
| AU2002348498A1 (en) | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | |
| AU2002339957A1 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| UA77447C2 (en) | Azabicyclic-substituted fused heteroaryls, a pharmaceutical composition based thereon | |
| TW200300673A (en) | Azabicyclic-phenyl-fused-heterocyclic compounds for treatement of disease | |
| TW201036969A (en) | CGRP receptor antagonists |